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ABSTRACT 
Tamara S. Roman: Identification of regulatory elements and functional variants at GWAS loci for human 
metabolic traits 
(Under the direction of Karen Mohlke) 
Cardiovascular disease (CVD) and type 2 diabetes (T2D) are major public health burdens in the 
United States. Metabolic risk factors for these diseases include increased triglyceride levels, decreased 
high-density lipoprotein cholesterol levels (HDL-C), and increased waist-hip ratio (WHR, a measure of 
body fat distribution). Genome-wide association studies (GWAS) have identified hundreds of loci for 
human metabolic traits and diseases. For many of these loci, the molecular and biological mechanisms 
are unknown. Many association signals are located in non-coding regions of the genome, and some of 
the associated variants are located within regulatory elements. Due to linkage disequilibrium, the GWAS 
identified variants may serve as proxies for the true functional variants. Functional follow-up studies are 
necessary to identify the functional variant(s) at a locus, determine the target gene(s) and mechanisms 
for how the variants and genes influence metabolic traits.  
I identified functional regulatory variants and elements at three GWAS loci for metabolic traits. At 
the GALNT2 locus for HDL-C, at least two regulatory variants demonstrated allelic differences in 
transcriptional enhancer activity and transcription factor binding. The alleles associated with increased 
HDL-C demonstrated increased GALNT2 expression in human hepatocytes and subcutaneous adipose 
tissue samples. At the ADCY5 locus for T2D and glucose-related traits, I identified a regulatory variant 
located within an enhancer element in human pancreatic islets that exhibited allelic differences in 
enhancer activity, differential transcription factor binding, and allelic differences in regulatory H3K27ac 
ChIP-seq reads from human islets. The T2D risk allele showed lower ADCY5 expression in human islets. 
At the PLXND1 locus for WHR, I identified at least 4 enhancer elements in human umbilical vein 
endothelial cells, one of which also showed enhancer activity in zebrafish endothelial cells.  
Functional studies helped to identify regulatory variants, elements and target genes underlying 
these three association signals, and provided evidence that some GWAS loci have multiple regulatory
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variants that act to influence gene expression. Identification of functional variants will enable the 
characterization of the molecular mechanisms and direction of effect in humans, leading to a greater 
understanding of the relationship between these variants and target genes with metabolic traits and 
disease.
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CHAPTER 1: INTRODUCTION 
1.1  Cardiovascular disease 
Cardiovascular disease (CVD) is a leading cause of death worldwide and a major public health 
burden[1, 2]. An estimated 86 million adults in the United States suffer from CVD, a term that 
encompasses numerous medical conditions, including high blood pressure, myocardial infarction, stroke, 
and heart failure[3]. An estimated 43.9% of the United States population is predicted to develop some 
form of CVD by 2030, with medical costs projected to be about $918 billion[3, 4]. There are many major 
risk factors for CVD, including increased triglyceride and low-density lipoprotein cholesterol (LDL-C) levels, 
and decreased high-density lipoprotein cholesterol (HDL-C) levels[5-8]. Obesity and fat deposition also 
contribute to CVD risk[3, 9]. Increased visceral abdominal and extra-pericardial mediastinal fat deposition 
were found to be associated with an enhanced cardiovascular disease risk profile[10].  
 
1.2  Lipoproteins and cholesterol 
High total cholesterol levels increase an individual’s risk of cardiovascular disease and other 
adverse metabolic traits[11]. HDL-C (high-density lipoprotein cholesterol) and LDL-C (low-density 
lipoprotein cholesterol) are two major components of total cholesterol levels. LDL-C is a major focus with 
regards to risk of cardiovascular disease[12]. LDL particles consist of a core of triglycerides and 
cholesteryl esters surrounded by phospholipids, free cholesterol and the protein apolipoprotein B-100[13] 
and can become oxidized and accumulate in arteries, where inflammation and atherosclerosis can 
result[14]. In contrast to LDL, HDL particles are smaller in size[15]. HDL-C levels are inversely associated 
with atherosclerotic cardiovascular disease[16, 17]. Like LDL, HDL consists of phospholipids, free 
cholesterol, apolipoproteins, and a core of triglycerides and cholesteryl esters, however, its major 
proteincomponent is Apolipoprotein A-1[18]. Apolipoprotein A-1 facilitates reverse cholesterol transport, 
which may be a critical function in preventing atherosclerosis[19-23]. Reverse cholesterol transport
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involves the efflux of cholesterol from macrophages in the arteries and cholesterol transport back to the 
liver[24-26]. 
 
1.3  Type 2 diabetes 
Diabetes has also become a health epidemic within the United States. An estimated 21.1 million 
adults have diagnosed diabetes, with estimated medical costs at $245 billion in 2012[2, 27]. Type 2 
diabetes (T2D) is the primary type of diabetes in adults, consisting of 90-95% of diagnosed cases[2]. T2D 
is characterized by impaired fasting glucose and/or impaired glucose tolerance[28]. These characteristics 
can be the result of insulin resistance or impaired insulin secretion through pancreatic beta cell 
dysfunction[29]. Individuals with type 2 diabetes can also develop vascular and circulatory abnormalities 
that can lead to the development of cardiovascular disease[30]. Circulatory disorders associated with 
diabetes include coronary heart disease, congestive heart failure and stroke[31]. Fasting insulin levels 
were found to be associated with coronary heart disease incidence[32] and individuals with type 2 
diabetes are at increased risk of coronary atherosclerosis[33] and death from coronary heart disease[34]. 
 
1.4  Obesity and body fat distribution 
Obesity and excess body fat contribute type 2 diabetes and cardiovascular disease risk. An 
estimated 35% of adults in the United States are obese[2]. Obesity can occur with other comorbid 
conditions such as hypertension, hypercholesterolemia, and hypertriglyceridemia[35], all of which can 
increase risk of type 2 diabetes and cardiovascular disease[36]. Waist-hip ratio (WHR) a measurement of 
body fat distribution, also influences cardiometabolic traits. Increased WHR is a common anthropometric 
index for visceral fat accumulation[37]; WHR values of 0.9 to 1.0 in men and 0.8 to 0.9 in women have 
been thought to confer an increased risk of adverse metabolic risk factors[37-40]. Increased abdominal 
visceral adipose tissue (VAT) has been shown to be associated with higher triglyceride and lower HDL-C 
in men and women[41]. Additionally, increased expression of inflammatory genes[42] and macrophage 
infiltration[43] have been observed in omental (visceral) fat compared with subcutaneous fat. Elevated 
serum free fatty acids from visceral fat lipolysis can increase pancreatic insulin secretion and endothelial 
dysfunction, and decrease insulin sensitivity in muscle and liver[44]. Increased free fatty acids from 
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visceral fat can also contribute to increased hepatic triglycerides, nonalcoholic fatty liver disease and 
insulin resistance[45]. Studies have shown that insulin resistance, increased triglycerides, and central 
obesity tend to cluster together[46, 47] and contribute to a metabolic disease risk profile.  
 
1.5  Genetics of cardiometabolic traits 
While environment, lifestyle and diet can influence cardiovascular disease, blood lipid and 
cholesterol levels, type 2 diabetes and body fat distribution[2, 48, 49], there is also a heritable component 
to these traits and diseases[50-52]. Heritability estimates for blood lipid and cholesterol levels range from 
40-90%[53-58]. Heritability estimates for type 2 diabetes range from 30-77%[59, 60] and heritability 
estimates for body fat distribution (as measured by WHR) range from 31-70%[40, 55, 61, 62]. 
Genome-wide association studies (GWAS) have identified over 150 loci associated with blood 
lipid and cholesterol levels[63] over 45 loci associated with WHR[64, 65] and over 70 loci associated with 
type 2 diabetes[66, 67].GWAS provide an unbiased approach to identify candidate genes that may 
influence a particular trait or disease. Although GWAS have identified DNA variants and candidate genes 
associated with a trait or disease, they do not indicate which variants are functional. DNA variants 
inherited together and in strong linkage disequilibrium (LD) with the trait-associated variant may be 
responsible for driving the association signal, with the identified associated variant serving as a proxy[68]. 
Therefore, functional follow-up studies of association signals are necessary to determine the true 
functional variants and genes and to identify novel drug targets.  
 
1.6  Identifying functional regulatory DNA variants from GWAS 
Identification of the functional variants underlying an association signal from GWAS can help to 
characterize a molecular mechanism for how the variants may be acting on a gene. Further, it can lead to 
the better understanding of how genes play a role in a biological process or disease. In one example, a 
study at the SORT1 locus identified a functional variant and molecular mechanism underlying association 
with LDL-C and myocardial infarction risk, and also elucidated novel biology by connecting SORT1 gene 
function to LDL-C metabolism[69]. In another example, GWAS identified SNPs associated with HDL-C, 
LDL-C, triglyceride levels and myocardial infarction near the TRIB1 gene[70], and subsequent studies of 
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Trib1 overexpression in mouse liver resulted in decreased lipid and cholesterol levels[71], providing a 
direct connection between gene function and CVD risk factors. Many DNA variants identified through 
GWAS are located within noncoding or intergenic regions of the genome[68], therefore, the variants may 
be located within enhancer or repressor elements that may ultimately alter gene expression, in contrast to 
altering the structure or function of a protein.  
The ENCODE Project has numerous datasets to annotate functional genomic elements, including 
regulatory elements[72]. The NIH Roadmap Epigenomics Consortium has also created a resource that 
includes regulatory datasets for over 100 reference human epigenomes from a wide variety of cell types 
and tissues[73]. Both the ENCODE Project and NIH Roadmap Epigenomics Consortium resources 
include datasets that distinguish open chromatin regions that are devoid of histone proteins and are 
therefore more accessible to transcription factors. Two well-established methods for identifying open 
chromatin include DNase I hypersensitivity sequencing (DNase-seq) and formaldehyde-assisted isolation 
of regulatory elements (FAIRE) sequencing. DNase-seq involves DNase I enzyme digestion of DNA in 
regions devoid of histones (“open chromatin”) and subsequent sequencing[74]. FAIRE involves 
crosslinking histones to DNA and then isolating the open chromatin regions by phenol-chloroform 
extraction[75]. Both methods detect more active regulatory regions of DNA, including promoters and 
enhancers, which are more accessible to transcription factors. Chromatin immunoprecipitation 
sequencing (ChIP-seq) of histone modifications can also distinguish regulatory regions of DNA. Enhancer 
regions are often marked by H3K4me1 and/or H3K4me2 (mono- or di-methylation of lysine 4 on histone 
H3), while promoter regions typically are marked by H3K4me3[76]. Furthermore, active enhancers often 
can be distinguished by the histone modification H3K27ac[77]. Transcription factor ChIP-seq data can 
also be used to detect regulatory regions in which transcription factors are bound[78]. Open chromatin 
and histone modifications have been used to guide the identification of functional regulatory variants[79-
85]. 
 
1.7  Aims and overview 
The main aims of this dissertation are to identify the functional variants and regulatory elements 
at the HDL-C-associated GALNT2 locus, the type 2 diabetes and glycemic trait-associated ADCY5 locus, 
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and the WHR-associated PLXND1 locus, and to further characterize the molecular mechanisms by which 
the functional variants act. The association signals at the GALNT2, ADCY5 and PLXND1 loci are all 
located within noncoding regions, therefore, I aimed to investigate whether any of the variants are located 
within regulatory regions and whether the variants show allelic differences in regulatory activity. At these 
three loci, open chromatin, histone modification ChIP-seq and transcription factor ChIP-seq data were 
considered in order to identify potential regulatory elements and variants. 
In Chapter 2, the GALNT2 HDL-C-association signal was further characterized by using fine-
mapping and conditional analyses in 10,079 individuals from the METSIM study. I comprehensively 
evaluated the transcriptional regulatory activity of all candidate variants in strong linkage disequilibrium (r
2 
> 0.7) with the lead HDL-C GWAS variant, rs4846914. For the variants that showed allelic or haplotype 
differences in transcriptional regulatory activity, I tested for evidence of differential protein binding to the 
alleles using electrophoretic mobility shift assays (EMSAs), and confirmed the identity of the factors 
bound to 2 of the regulatory variants using EMSA supershift and ChIP assays. I also evaluated whether 
using regulatory datasets (i.e. open chromatin, histone modification ChIP-seq and transcription factor 
ChIP-seq data) can help to distinguish variants that show allelic differences in regulatory activity from a 
set of candidate variants. Finally, I describe the direction of effect using allelic expression imbalance 
assays in primary hepatocytes and expression quantitative trait locus (eQTL) lookups in primary 
subcutaneous adipose samples to show that the rs4846914-A allele (associated with increased HDL-C) is 
associated with increased GALNT2 expression. 
In Chapter 3, I used open chromatin and chromatin state regulatory datasets in human pancreatic 
islets to identify a candidate functional regulatory variant, rs11708067, which was associated with type 2 
diabetes and glycemic traits at the ADCY5 locus. I tested and confirmed that this variant showed allelic 
differences in transcriptional activity in mouse and rat insulinoma beta cell lines, as well as allelic 
differences in protein binding in EMSAs. Additionally, H3K27ac ChIP-seq reads spanning this variant in a 
human pancreatic islet sample were evaluated for allelic imbalance. Finally, I describe the direction of 
effect using both new and previously published eQTL data and provide a proposed model in which the 
T2D risk- and glucose-raising-A allele of rs11708067 results in decreased ADCY5 expression. 
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In Chapter 4, I describe the identification of regulatory elements at the PLXND1 locus. GWAS 
identified a human WHR association signal that spans upstream of the PLXND1 promoter and PLXND1 
intron 1. Considering its established role in vascular biology, visceral adipose tissue morphology and lipid 
storage, PLXND1 is a strong candidate gene that may influence human body fat distribution. Through the 
use of complementary assays in human cell lines and zebrafish, I examine the regulatory activity of 
candidate regulatory elements at the PLXND1 locus and show that one of these candidate elements 
shows regulatory enhancer activity in both HUVEC and in zebrafish endothelial cells. 
In Chapter 5, I summarize the findings highlighted in Chapters 2, 3 and 4 and discuss the lessons 
learned from my functional follow-up studies on three GWAS signals for metabolic complex traits.
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CHAPTER 2: MULTIPLE HEPATIC REGULATORY VARIANTS AT THE GALNT2 GWAS LOCUS 
ASSOCIATED WITH HIGH-DENSITY LIPOPROTEIN CHOLESTEROL
1 
 
2.1 Introduction 
Genome-wide association studies (GWASs) have identified more than 150 loci associated with 
blood lipid and cholesterol levels[63, 86-89]. One of the first novel GWAS signals for high-density 
lipoprotein cholesterol (HDL-C) levels in Europeans was reported for variants rs2144300 and rs4846914, 
located within intron 1 of GALNT2[70, 90] (MIM: 602274). These two lead GWAS variants are in perfect 
linkage disequilibrium (LD; r
2 
= 1). The association signal for rs4846914 has been replicated (n = 187,000 
individuals, p = 4 × 10
−41
) in subsequent studies with larger sample sizes[63, 87] and in Japanese and 
Mexican populations[91, 92]. HDL-C-associated variant rs4846914 is also associated (n = 178,000, p = 7 
× 10
−31
) with triglycerides[63] and nominally associated (n = 2,744–3,481, p < 0.05) with large HDL 
concentration, low-density lipoprotein (LDL) size, HDL size, HDL-2 subfraction, and the ratio of total 
cholesterol to HDL-C[93]. The alleles associated with increased HDL-C are also nominally associated (n 
= 84,068, p = 0.04) with decreased risk of coronary artery disease[63].  
According to 1000 Genomes phase 1 version 3 European (EUR) data[94] 24 variants exhibit 
strong LD (r
2
 > 0.7) with the lead GALNT2 HDL-C-associated SNP, rs4846914, and all 25 variants are 
noncoding. According to available chromatin data from the ENCODE Project[72] and Human Epigenome 
Atlas[73] these variants overlap many candidate regulatory regions. Therefore, we hypothesized that one 
or more of these variants regulate gene expression. Many variants identified through GWASs are located 
within noncoding or intergenic regions[68, 95] and variants at the GALNT2 locus might also alter 
regulatory elements. 
GALNT2, encoding UDP-N-acetylgalactosamine:polypeptide N-acetylgalactosaminyltransferase 
(GALNT2), is a reasonable positional candidate within the HDL-C association signal. GALNT2 is an
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enzyme that transfers an N-acetylgalactosamine to serine or threonine residues in target proteins in the 
initial step of O-linked glycosylation[96]. GALNT2 is expressed in many tissues, including liver, heart, lung, 
muscle, pancreas, ovary, and colon[97-99]. GALNT2 might influence HDL-C levels by catalyzing O-
glycosylation on target proteins that play a role in lipid metabolism. In vitro, GALNT2 has been shown to 
O-glycosylate lecithin-cholesterol acyltransferase (LCAT), phospholipid transfer protein (PLTP), and 
angiopoietin-like protein 3 (ANGPTL3), and O-glycosylation of ANGPTL3 was shown to inhibit activation 
of this protein[100]. Individuals heterozygous for a GALNT2 missense variant (c.941A>C [p.Asp314Ala]) 
shown to decrease GALNT2 function in vitro exhibit decreased glycosylation of apoC-III and high (>95
th
 
percentile for age and gender) plasma HDL levels[101]. In mice, liver-specific Galnt2 overexpression and 
knockdown have been shown to decrease and increase HDL-C levels, respectively[87].  
We aimed to identify the functional regulatory variant(s) responsible for the GALNT2 HDL-C 
GWAS signal by fine mapping the association with lipoprotein traits in the METSIM (Metabolic Syndrome 
in Men) study[102] and by examining a comprehensive set of candidate variants for evidence of allelic 
differences in enhancer function. We identified a single signal driven by at least two regulatory variants, 
rs4846913 and rs2281721, that exhibited binding of transcription factors and allelic differences in 
enhancer activity, as well as additional variants that might contribute to enhancer function. In human 
hepatocyte and subcutaneous adipose tissue samples, we observed an association between this GWAS 
signal and GALNT2 expression. Together, these data show a consistent direction of regulatory effect in 
which increased expression of GALNT2 is implicated in increased HDL-C. 
 
2.2 Materials and Methods 
2.2.1 Defining the candidate set of variants 
We used the 1000 Genomes Project Phase 1 version 3 EUR dataset[94] including 24 variants in 
strong LD (r
2
 > 0.7) with the lead HDL-C GWAS SNP rs4846914, to calculate LD. We used ENCODE 
data[72] available through the UCSC Genome Browser to determine which of the 25 total variants 
overlapped open-chromatin peaks and chromatin-immunoprecipitation-sequencing (ChIP-seq) peaks of 
histone modifications H3K4me1, H3K4me2, H3K4me3, H3K9ac, and H3K27ac and transcription factors 
in liver cell types (HepG2 cells, Huh-7 cells, and primary human hepatocytes) and ChromHMM chromatin 
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states[103] in multiple cell types. We used the Human Epigenome Atlas[73] to determine overlap with 
peaks of H3K4me1 and H3K9ac in primary adult liver and with ChromHMM chromatin states in multiple 
cell types and tissues. 
 
2.2.2 Genotyping and imputation 
We used the Illumina HumanOmniExpress and HumanCoreExome[104] Beadchips to genotype 
10,134 Finnish men from the METSIM study[102]. Sample-level and SNP-level quality control included 
detecting sample contamination[105] confirming sex and relationships, and using principal-component 
analysis to detect population outliers. After we filtered SNPs to retain those with a call rate of >95% and 
Hardy-Weinberg Equilibrium p > 10
−6
, we successfully analyzed 10,082 individuals and 681,803 SNPs. 
The METSIM study was approved by the ethics committee of the University of Kuopio and Kuopio 
University Hospital, and informed consent was obtained from all study participants. To impute 
ungenotyped SNPs, we used a panel of 5,474 reference haplotypes derived from genome sequences of 
2,737 central-northern European individuals sequenced as part of the Genetics of Type 2 Diabetes study 
(C.F., J. Flannick, K.J.G., H. Kang, and the GoT2D Consortium, unpublished data). The minimum MaCH 
imputation quality score for the imputed variants was R
2
 = 0.971. We used a two-step imputation strategy 
wherein individuals were pre-phased with ShapeIT version 2 before imputation using Minimac[106]. We 
also used these data to verify LD proxies for allelic-expression-imbalance (AEI) assays. 
 
2.2.3 Fine-mapping and conditional analyses 
We analyzed 72 measures of lipid and lipoprotein particle-serum concentration obtained via 
nuclear-magnetic-resonance (NMR) metabolomics (65 traits) or enzymatic assays (7 traits) in up to 
10,079 Finnish men. The NMR platform has been described previously[107, 108]. The methodology for 
measuring lipoprotein subclasses has been described previously[15] and subclasses are defined in Table 
2.1. Trait values with skewed distributions were log transformed, and all traits were Winsorized at 5 SDs 
from the mean. After adjustment for age, squared age, smoking status, and lipid-lowering-medication 
status, we transformed residuals to a standard normal. We tested for association between normalized 
residuals and SNPs with a minor allele frequency (MAF) > 0.0005 (minor allele count > 10) by assuming 
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an additive genetic model and using a linear mixed model with an empirical kinship matrix to account for 
relatedness, as implemented in EMMAX[109]. We repeated the analysis while excluding individuals on 
lipid-lowering medication (2,844 participants), individuals with type 1 or 2 diabetes (1,420 participants), or 
both (3,560 participants) to assess sensitivity to these exclusions, and in each instance we obtained 
qualitatively similar results. To identify any additional independent signals in the region, we performed a 
conditional analysis by using the rs17315646 allele count as an additional covariate in the model. 
LocusZoom[110] plots were generated to include 2,079 variants in a 350-kb region surrounding the lead 
variant rs17315646 and spanning GALNT2. 
 
2.2.4 Cell culture 
Human HepG2 hepatocellular carcinoma cells (ATCC, HB-8065) were grown in Eagle’s minimum 
essential medium (MEM) alpha supplemented with 10% fetal bovine serum (FBS) and 1 mM sodium 
pyruvate at 37°C and 5% CO2. Human Huh-7 hepatocellular carcinoma cell lines (JCRB0403, Japanese 
Collection of Research Bioresources Cell Bank, National Institute of Biomedical Innovation) were grown in 
DMEM supplemented with 10% FBS, 1 mM sodium pyruvate, 1× MEM non-essential amino acids, and 
2 mM L-glutamine. HepG2 and Huh-7 cells were seeded into 24-well plates (100,000 cells per well) 1 day 
prior to transfection experiments. 
 
2.2.5 Transcriptional reporter assays 
To test candidate variants and haplotypes for allele-specific effects on transcriptional activity, we 
amplified segments of 109–262 bp (for single variants) and 349–780 bp (for multiple variants) from DNA 
of individuals homozygous for each allele or haplotype. Segment size was chosen to include the ∼147 
nucleotides of DNA spanning one nucleosome. However, because of the proximity of other candidate 
variants, larger segments of 349–780 bp were designed to include multiple variants. Primer sequences 
are listed in Table 2.2. Amplicons were cloned into the KpnI and XhoI restriction sites of the firefly 
luciferase transcriptional reporter vector pGL4.23 in both forward and reverse orientations with respect to 
the minimal promoter (Promega). Three to seven independent plasmids for each allele or haplotype were 
isolated and confirmed by sequencing. When additional variants were identified, we selected clones for 
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which the alleles matched at these variants. For simplicity of presentation, Figures 2.4, 2.6 and 2.7 do not 
show the differing alleles of rs1555290; these data are provided in Figures 2.8 and 2.9. We then 
transfected each purified clone into HepG2 or Huh-7 cells in duplicate (720 ng in each well) by using 
FuGENE 6 (Promega) and Opti-MEM (Life Technologies). To control for transfection efficiency, we co-
transfected a phRL-TK Renilla luciferase reporter vector (80 ng in each well) into cells. For empty-vector 
controls, two independent preparations of empty vector were each transfected into HepG2 or Huh-7 cells 
in duplicate. After 48 hr, cell-lysate luciferase activity was measured with the Dual-Luciferase Reporter 
Assay System (Promega), normalized, and compared to readings for empty-vector controls. These 
control readings were very similar for the two independent preparations. We performed two-tailed t tests 
to compare the luciferase activities between variant alleles. For comparisons of multiple haplotypes, we 
performed ANOVA and Tukey’s post hoc tests by using JMP 10.0.1 software (SAS Institute). We also 
assessed the transcriptional activity of the 780-bp segment by cloning the haplotype into the promoterless 
pGL4.10 firefly luciferase reporter vector (Promega). To examine individual variant effects within the 780-
bp segment, we altered alleles by using the QuikChange Site-Directed Mutagenesis Kit (Agilent 
Technologies) and confirmed them by sequencing. 
 
2.2.6 Electrophoretic mobility shift assays 
Complementary DNA oligonucleotides (17–19 bp) centered on variant alleles (Table 2.2) were 
synthesized by Integrated DNA Technologies. The rs6143660 insertion allele consisted of 39-bp 
complementary oligonucleotides containing the 21-bp insertion (9 bp flanking each side of the insertion), 
and the rs6143660 deletion allele consisted of 18-bp complementary oligonucleotides (9 bp flanking each 
side of the deleted sequence). Labeled oligonucleotides included biotin on the 5′ end. We performed 
assays as previously described[83] by using 3.5–6 μg of HepG2 nuclear lysate and 30- to 300-fold excess 
unlabeled probe. For supershift reactions, 4–8 μg CEBPB antibody (sc-150X), USF1 antibody (sc-229X), 
and FOXO3 antibody (sc-34895X), all from Santa Cruz Biotechnology, were incubated with binding buffer, 
poly(dI·dC), and HepG2 nuclear lysate for 20 min at room temperature before the addition of labeled DNA 
probes and incubation. Additional control antibodies (4–6 μg, all from Santa Cruz Biotechnology) were 
chosen on the basis of transcription-factor binding motifs, ENCODE ChIP-seq peaks, expression of 
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transcription factors in liver, or plausible roles of the factors in cholesterol metabolism. These included 
antibodies to ARNT (sc-271801X), SF1 (sc-10976X), HNF4A (sc-6556X), RXRA (sc-553X), CEBPA (sc-
61X), CEBPB (sc-150X), NR1H3 (sc-1202X), and MAX (sc-765X). Reactions were loaded into a 6% DNA 
retardation gel (Life Technologies), subjected to electrophoresis, transferred to Biodyne B nylon 
membranes (Life Technologies), and UV crosslinked. Wash and detection steps were performed 
according to instructions in the Chemiluminescent Nucleic Acid Detection Module (Life Technologies). 
Experiments involving electrophoretic mobility shift assays (EMSAs) were repeated on 2–7 separate days, 
and all had consistent results. 
To predict transcription-factor binding sites, we searched databases for transcription-factor 
binding-site motifs in 17- to 21-bp genomic sequences containing each allele of candidate variants. For 
JASPAR[111] we searched all available matrix models with a relative profile-score threshold of 80%. We 
also searched positional-weight matrices (PWMs) from vertebrates in TRANSFAC by using default 
parameters in the TRANSFAC Professional’s Match tool and by using PWM-SCAN[112]. 
 
2.2.7 ChIP assays 
We used a TaqMan SNP Genotyping Assay (Life Technologies) to genotype HepG2 and Huh-7 
cells at rs4846913. Cells were crosslinked with 1% formaldehyde, and glycine was added to stop fixation. 
Fixed cells were resuspended in SDS lysis buffer (1% SDS, 10 mM EDTA, and 50 mM Tris [pH 8.1]), 
diluted with immunoprecipitation (IP) buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris 
[pH 8.1], and 167 mM NaCl), and sonicated on ice with a Branson sonifier for the generation of 100- to 
500-bp DNA fragments. Each CEBPB IP or immunoglobulin G (IgG) reaction used two to three million 
cells. After preclearing with Protein A Agarose beads (sc-2001, Santa Cruz Biotechnology), 10 μg of 
CEBPB antibody (sc-150X, Santa Cruz Biotechnology) or 10 μg of normal rabbit IgG (sc-2027, Santa 
Cruz Biotechnology) was added to HepG2 and Huh-7 cell lysates and incubated overnight. Protein A 
Agarose beads were then added for 3 hr and washed separately with low-salt buffer, high-salt buffer, LiCl 
buffer, 10 mM Tris-EDTA, and elution buffer (1% SDS and 0.1 M NaHCO3). The crosslinks were then 
reversed by the addition of 5 M NaCl and overnight incubation. Samples were incubated with 20 μl 1M 
Tris, 10 μl 0.5 M EDTA, and 0.03 mg proteinase K. DNA was purified by phenol-chloroform extraction and 
 13 
ethanol precipitation. For qPCR, a 120-bp region spanning rs4846913 was amplified with FAST SYBR 
Green Master Mix (Life Technologies). qPCR was performed in triplicate and quantified with respect to a 
standard curve generated from sonicated HepG2 DNA standards. The mean quantities of CEBPB IP and 
IgG control sample were normalized to input HepG2 or Huh-7 DNA. CEBPB and IgG ChIP experiments 
with HepG2 and Huh-7 cells were each performed twice and had similar results. We used two-tailed t 
tests to compare CEBPB enrichment of the rs4846913 region in HepG2 and Huh-7 cells. 
We performed USF1 ChIP assays similarly, except that we used a Diagenode Bioruptor Standard 
sonicator. We used 10 μg of USF1 antibody (sc-229X, Santa Cruz Biotechnology) or 10 μg IgG (sc-2027, 
Santa Cruz Biotechnology) and purified DNA with the QIAquick PCR Purification Kit (QIAGEN) to amplify 
and quantify a 164-bp region spanning rs2281721. We performed USF1 and IgG ChIP experiments with 
HepG2 and Huh-7 cells twice each, and they had similar results. 
 
2.2.8 Allelic-imbalance analysis of sequence reads from CEBPB ChIP-seq and DNase-seq 
Sequence reads from HepG2 for DNase-I-hypersensitivity-site sequencing (DNase-seq) and 
CEBPβ ChIP-seq experiments generated by the ENCODE Consortium[72] were aligned to UCSC 
Genome Browser build hg19 with AA-ALIGNER[113]. In brief, HepG2 genotypes were obtained from the 
Illumina Human-1M-Duo BeadChip array genotyped at HusdonAlpha Institute of Biotechnology, and 
imputation was performed with the 1000 Genomes Phase 1 EUR reference panel[94]. Using this data, we 
verified that HepG2 is diploid in the chromosome 1 region containing GALNT2, and we created a 
personalized HepG2 reference genome containing non-reference alleles for sites at which HepG2 is 
homozygous for the non-reference allele. We aligned sequence reads to the personalized genome by 
using HepG2 heterozygous sites identified by imputation and GSNAP[114] with the following parameters: 
-m 1, -k 11, --basesize = 11, -sampling = 1, -terminal-threshold = 10, -n 1, -query-unk-mismatch = 1, -
genome-unk-mismatch = 1, -trim-mismatch-score = 0, -t 7, and --A sam. We filtered the alignments to 
remove sequences aligned to more than one genomic location, sequences aligned to regions 
underrepresented in the reference sequence (ENCODE blacklisted[72] regions), and duplicate reads that 
might represent PCR artifacts. We determined the significance of allelic imbalance at rs4846913 by using 
an exact binomial test, based on the number of reads containing the reference allele and the total number 
 14 
of reads at the heterozygous site. For the HepG2 DNase-seq data and USF1 HepG2 ChIP-seq data, 
insufficient reads were available for allelic imbalance analysis at rs2281721. 
 
2.2.9 Preparation of cDNA for GALNT2 mRNA-expression and AEI assays 
RNA and DNA were isolated from hepatocyte samples of 50 individuals as described 
previously[115] RNA for each sample was treated with DNase I with the DNA-free Kit (Life Technologies) 
and added to a final concentration of 24 ng/μl in an RT-PCR reaction in the SuperScript III First-Strand 
Synthesis System (Life Technologies), which includes both oligo(dT)20 and random hexamer primers. The 
synthesized cDNA for each sample was then diluted with diethylpyrocarbonate (DEPC)-treated water for 
use in mRNA-expression and AEI assays. 
 
2.2.10 AEI assays 
We used a TaqMan SNP genotyping assay (Life Technologies) to genotype human hepatocyte 
genomic DNA (gDNA) from ADMET Technologies for the HDL-C index SNP rs4846914. To quantify 
allele-specific expression, we diluted hepatocyte cDNA and gDNA from 36 individuals heterozygous for 
rs4846914 and performed subsequent qPCR reactions in triplicate. To generate a standard curve, we 
mixed gDNAs from samples homozygous for each rs4846914 allele in the following ratios: 95:5, 72.5:27.5, 
61.25:38.75, 50:50, 38.75:61.25, 27.5:72.5, and 5:95. We generated a standard curve by plotting the 
quantity of one allele against the difference between the cycle-threshold (Ct) values of the two alleles. For 
each heterozygous sample, we estimated the expression percentage of one allele by using the difference 
between the mean Ct values of the alleles and the standard curve[115]. We used two-tailed t tests to 
compare gDNA and cDNA values and used F-tests to determine equal or unequal variance between 
gDNA and cDNA samples[115, 116]. 
 
2.2.11 GALNT2 hepatocyte mRNA expression 
We measured expression of GALNT2 in 50 human hepatocyte samples by qPCR with a standard 
curve and FAST SYBR Green Master Mix (Life Technologies). We performed triplicate qPCR reactions 
including 9 ng of total cDNA in each well, Taqman Gene Expression Master Mix (Life Technologies), and 
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primer-set sequences within GALNT2 exons (Table 2.2). GALNT2 expression values were normalized to 
the expression of beta-2-microglobulin (B2M [MIM: 109700]), natural-log transformed, and plotted 
according to the rs4846914 genotype (AA, AG, and GG). Using linear regression and an additive model 
including sex, ancestry, and age as covariates, we tested for association between the level 
of GALNT2 mRNA and the rs4846914 genotype. 
 
2.2.12 Lookup of expression quantitative trait loci in subcutaneous adipose tissue 
We looked for evidence of association between the HDL-C GWAS variant region and gene 
expression by using preliminary microarray expression data from subcutaneous adipose tissue from the 
METSIM study. In brief, we used EPACTS-multi (with EMMAX implemented to account for family 
relatedness) Affymetrix Human Genome U219 Array data for 1381 individuals was adjusted for 40 
confounding factors[117] inverse-normal transformed, and tested for association with variants. We 
analyzed variants within 1 Mb of rs4846914 and identified one probe set for GALNT2 and other genes 
located in this region. Subsequent reciprocal conditional analyses included two variants in each model. 
 
2.2.13 siRNA-mediated knockdown of CEBPB 
HepG2 cells (80,000 per well) were plated into 24-well collagen-coated plates and then treated 
with 50 nM CEBPB Silencer Select small interfering RNA (siRNA; s2893, Thermo Fisher Scientific) or 
Silencer Select Negative Control No. 1 siRNA (4390843, Thermo Fisher Scientific) with Opti-MEM (Life 
Technologies) and DharmaFECT1 transfection reagent (GE Healthcare Life Sciences) on the following 
day. Cells were incubated at 37°C with 5% CO2 for 48 hr, and HepG2 medium was changed the day 
following siRNA transfection. RNA was harvested with the RNeasy Plus Mini Kit (QIAGEN), and cDNA 
was prepared with the SuperScript III First-Strand Synthesis System (Life Technologies). CEBPB and 
GALNT2 expression was measured by qPCR with a standard curve. Raw expression values were 
normalized to the expression of B2M, and expression percentages were calculated by comparison to 
expression values in HepG2 cells transfected with the negative control siRNA. Primers for gene 
expression are listed in Table 2.2. We used two-tailed t tests to compare normalized GALNT2 expression 
between HepG2 cells treated with CEBPB siRNA and HepG2 cells treated with negative control siRNA. 
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2.3 Results 
2.3.1 Fine mapping shows evidence of a single association signal strongest for total cholesterol 
in medium HDL 
We tested one of the HDL-C-associated lead GWAS variants, rs2144300 (r
2
 = 1 with rs4846914), 
for association with 72 lipid and cholesterol traits in up to 10,079 Finnish men from the METSIM study. 
The strongest evidence of association across all 72 traits was with total cholesterol in medium HDL (n = 
9,810, β = 0.10, p = 5.3 × 10
−12
; Table 2.3). Using this trait and variants that were directly genotyped or 
imputed from a reference panel of 2,737 genomes of central-northern European individuals, we 
performed fine-mapping association and conditional analyses. Among 2,079 total variants in the region 
spanning 350 kb surrounding the lead variant, the strongest evidence of association was observed for 
rs17315646 (n = 9,810, p = 3.5 × 10
−12
), which is in perfect LD (r
2
 = 1) with HDL-C GWAS lead SNPs 
rs4846914 (n = 9,810, p = 5.3 × 10
−12
) and rs2144300 (n = 9,810, p = 5.3 × 10
−12
). Conditioning on 
rs17315646 attenuated the 13.7-kb association signal (all p > 0.01; Figure 2.1 and Table 2.4). The new 
lead variants after conditional analysis (pcond ∼ 10
−4
–10
−6
) showed weak initial evidence of association (p 
∼ 10−2–10−4) and have a MAF < 0.04 (Table 2.4). These data provide evidence that common variants in 
strong LD with rs4846914 and rs17315646 are most likely responsible for the HDL-C association signal. 
All 25 candidate variants (r
2
 > 0.7 with HDL-C GWAS lead variant rs4846914) are located within intron 1 
of GALNT2. These variants all exhibited strong evidence of association with total cholesterol in medium 
HDL (p ≤ 1.45 × 10
−9
;Table 2.4). 
 
2.3.2 Open-chromatin, histone-modification, and transcription-factor marks indicate potential 
regulatory elements overlapping the GALNT2 association signal 
We hypothesized that one or more of the 25 HDL-C-associated non-coding variants affect 
transcriptional activity. We asked whether regulatory datasets from the ENCODE Project and Human 
Epigenome Atlas could help us identify variants that exhibit regulatory activity. We compared the location 
of the 25 candidate variants to regions of open chromatin depicted by DNase I hypersensitivity and 
formaldehyde-assisted isolation of regulatory elements (FAIRE); histone-modification ChIP-seq peaks 
H3K4me1, H3K4me2, H3K4me3, H3K9ac, and H3K27ac, which often mark enhancer or promoter 
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elements; and transcription-factor ChIP-seq peaks. On the basis of the liver’s key role in HDL synthesis 
and transport, and the enrichment of lipid GWAS signals in liver[63] we focused on datasets from human 
liver cell lines, primary human hepatocytes, and human adult liver cells. All 25 variants overlap broad 
patterns of H3K4me1-enriched domains in HepG2 cells (Table 2.5), and 13 overlap narrower H3K4me1-
enriched peaks[118]. Sixteen variants overlap two or more histone-modification peaks, and six variants 
(rs4631704, rs4846913, rs2144300, rs6143660, rs2281721, and rs11122453) overlap at least one 
transcription-factor ChIP-seq peak (Figure 2.2 and Table 2.5). Three variants (rs4846913, rs2144300, 
and rs6143660) overlap the most marks of potential regulatory function (at least 22 peaks, including 
open-chromatin, histone-modification, and transcription-factor peaks). According to ChromHMM data[103] 
from ENCODE[72] and the Roadmap Epigenomics Project[73] all 25 variants are located within predicted 
enhancer or transcribed-region chromatin states in HepG2 cells and primary liver cells (Figure 2.3). The 
regulatory peaks are not specific to liver cells, given that open-chromatin, histone-modification, and 
transcription-factor peaks were also observed in GM12878 lymphoblastoid cells, human umbilical-vein 
endothelial cells (HUVECs), K562 leukemia cells, CD20
+
 B cells, CD14
+
 monocytes, human skeletal-
muscle myoblasts (HSMMs), normal human astrocytes (NHAs), normal human lung fibroblasts (NHLFs), 
and osteoblasts (Figure 2.3). 
 
2.3.3 All 25 candidate regulatory variants were evaluated for allelic differences in luciferase 
activity 
Given the limited resolution of open-chromatin peaks and histone-modification and transcription-
factor ChIP-seq peaks, and the knowledge that these marks do not predict allelic differences in regulatory 
activity, we tested all 25 variants in transcriptional reporter assays in luciferase vectors containing a 
minimal promoter in HepG2 cells (Figures 2.4 and 2.5). Tested elements contained one to four variants, 
and three to seven independent clones for each allele or haplotype in the element were tested. We 
considered elements exhibiting >1.5-fold more activity than empty-vector controls as enhancers. We 
focused on elements whose enhancer activity in both forward and reverse orientations was >1.5-fold 
higher than that in the luciferase reporter gene alone, as well as differences (p < 0.05) between the alleles 
or haplotypes in both orientations. 
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2.3.4 rs2281721 exhibits allelic differences in transcriptional activity 
Among all the segments tested, a 154-bp DNA segment containing rs2281721 showed the 
strongest enhancement of luciferase activity, and this activity also differed between the alleles (Figure 
2.6A). In the forward orientation, the DNA segment containing the rs2281721 T allele, associated with 
increased HDL-C, showed 75-fold more luciferase activity than the empty-vector control, whereas the 
segment containing the rs2281721 C allele showed 27-fold more, and significant differences were 
observed between the alleles (p = 2.4 × 10
−6
). In the reverse orientation, the T and C alleles exhibited 37-
fold and 14-fold, respectively, more luciferase activity than did the control, and there were significant 
differences between the alleles (p = 5.8 × 10
−5
). The rs2281721 T allele also showed stronger enhancer 
activity than did the rs2281721 C allele in both forward (205-fold versus 59-fold more than in the control) 
and reverse (49-fold versus 19-fold more than in the control) orientations in a second hepatocellular 
carcinoma cell line, Huh-7 (both p < 3 × 10
−4
; Figure 2.7A). The segment and the position of rs2281721 
overlaps H3K4me1 peaks in HepG2 cells and adult liver; H3K4me2, H3K9ac, and H3K27ac peaks in 
HepG2 cells; and a USF1 transcription-factor ChIP-seq peak in HepG2 cells (Figure 2.2 and Table 2.5). 
 
2.3.5 A segment containing rs4846913, rs2144300, and rs6143660 shows haplotype differences 
in transcriptional activity 
A 780-bp DNA segment containing three variants exhibited significant haplotype differences in 
luciferase activity (Figure 2.6B). We analyzed two haplotypes of rs4846913, rs2144300, and rs6143660 
(a 21-bp indel): AT
−
 (containing the alleles associated with increased HDL-C) and CC
+
 (containing the 
alleles associated with decreased HDL-C). In the forward orientation, the AT
−
 and CC
+
 haplotypes 
showed 49-fold and 16-fold, respectively, more luciferase activity than did the empty-vector control, and 
significant differences were observed between the haplotypes (p = 1.8 × 10
−5
). In the reverse orientation, 
the AT
−
 and CC
+
 haplotypes exhibited 11-fold and 4-fold, respectively, more luciferase activity than did 
the empty-vector control, and significant differences were observed between the haplotypes (p = 2.0 × 
10
−4
). The three HDL-C-associated variants rs4846913, rs2144300, and rs6143660 (a 21-bp indel) each 
overlapped ≥22 open-chromatin, histone-modification, and transcription-factor peaks 
(Figure 2.2 and Table 2.5). 
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Haplotype effects on transcriptional activity were similar in Huh-7 cells. In the forward orientation, 
haplotypes AT
−
 and CC
+
 showed 36-fold and 13-fold, respectively, more luciferase activity than did the 
empty-vector control; the differences observed between the haplotypes were significant (p = 1.4 × 10
−5 
Figure 2.7B). In the reverse orientation, haplotypes AT
−
 and CC
+
 showed 12-fold and 6-fold, respectively, 
more luciferase activity than did the empty-vector control (p = 0.08,  Figure 2.7B). The direction of effect 
was the same as that of rs2281721; alleles associated with increased HDL-C showed increased 
luciferase activity. 
Taken together, our data show consistent haplotype differences in luciferase activity for a 780-bp 
segment consisting of rs4846913, rs2144300, and rs6143600. The results suggest that these variants are 
located within an enhancer element that can affect transcription and that one or more of them might have 
an allelic effect on transcriptional activity. 
 
2.3.6 The haplotype variants act together to regulate enhancer activity 
We then created additional haplotypes of the 780-bp segment by performing site-directed 
mutagenesis to investigate the variant responsible for allelic differences in transcriptional activity. In 
addition to including the candidate variants rs4846913, rs2144300, and rs6143660, the segment included 
an additional common variant, rs1555290, in moderate LD with rs4846914 (D′ = 1, r
2
 = 0.26). We 
analyzed and tested natural haplotypes of rs4846913, rs2144300, rs1555290, and rs6143660 (ATA
−
, 
CCC
+
, and CCA
+
), as well as constructed haplotypes CTA
−
, ACA
−
, CCA
−
, and CCC
−
. These seven 
haplotypes were then tested separately in luciferase assays (Figure 2.8 ). ATA
−
, CTA
−
, ACA
−
, and 
CCA
−
 haplotypes showed 44-fold, 38-fold, 31-fold, and 23-fold, respectively, more luciferase activity than 
did the empty-vector control, suggesting that both of the first two variants, rs4846913 and rs2144300, 
contribute to haplotype differences in transcriptional activity. Specifically, significant differences were 
observed between the ATA
−
 and ACA
−
 haplotypes (p = 0.04), between the CTA
−
 and CCA
− 
haplotypes 
(p = 0.04), and between the ATA
−
 versus CCA
−
 haplotypes (p = 0.001), supporting a contribution from 
both rs4846913 and rs2144300 to haplotype differences in luciferase activity. Compared to the control, 
the CCA
+
, CCC
−
, and CCC
+
 haplotypes showed similar 12- to 14-fold increases in luciferase activity (p > 
0.05; an intermediate between the CCA
−
 haplotype and the empty vector), suggesting that rs1555290 
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and/or rs6143660 might also contribute to increased transcriptional activity. We observed similar results in 
Huh-7 cells: the ATA
−
, ACA
−
, and CCA
−
 haplotypes showed 36-fold, 30-fold, and 27-fold, respectively, 
more luciferase activity than did the empty-vector control, and significant differences were observed 
between the ATA
−
 and CCC
−
 haplotypes (p = 0.0001). Compared to the empty-vector control, the CCA
+
, 
CCC
−
, and CCC
+
 haplotypes showed similar (p > 0.05) 13- to 15-fold increases in luciferase activity 
(Figure 2.9). Taken together, these data suggest a role for at least two variants, rs4846913 and 
rs2144300, in haplotype differences in enhancer activity. 
Because the SNPs in the 780-bp segment overlap H3K1me1 and H3K4me2 peaks, which are 
frequently present in enhancer regions, as well as a H3K4me3 peak, which is often found at promoters, 
we also evaluated the haplotypes in a promoterless vector (Figure 2.10). In the forward orientation, 
haplotypes ATA
−
, CCA
+
, and CCC
+
 showed 44-fold, 27-fold, 16-fold, respectively, more luciferase activity 
than did the empty-vector control, and significant differences were observed between all haplotype 
comparisons (p < 0.001). In the reverse orientation, haplotypes ATA
−
, CCA
+
, and CCC
+
 exhibited 12-fold, 
9-fold, and 5-fold, respectively, more luciferase activity than did the empty-vector control, and significant 
differences were observed between all the haplotype comparisons (p < 0.04). 
We subsequently analyzed the four variants individually in 100- to 200-bp DNA segments. Of the 
four variants tested individually, only the element containing rs2144300 exhibited enhanced luciferase 
activity (average 6.5-fold more than in the empty-vector control). Almost none of these segments showed 
allelic differences (p > 0.1; Figure 2.11), but rs4846913 did show allelic differences in only the forward 
orientation (p = 0.03). These data suggest that the larger segment is necessary for observing allelic 
differences in enhancer activity in this assay. 
 
2.3.7 USF1 binds to rs2281721 
To investigate whether transcription factors bind differentially to rs2281721, rs4846913, 
rs2144300, rs1555290, and rs6143660, we performed EMSAs with HepG2 nuclear lysate. The rs2281721 
C probe showed stronger protein binding than the rs2281721 T probe (lane 2 versus 7, 
arrow, Figure 2.12A). The addition of 40-fold excess unlabeled rs2281721 C probe competed away the 
signal more effectively than did unlabeled rs2281721 T probe (lane 3 versus 4). rs2281721 overlaps a 
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USF1 ChIP-seq peak from ENCODE data in HepG2 cells, as well as a predicted USF1 motif. In EMSAs, 
the addition of a USF1 antibody resulted in a disruption of the band observed with the C allele (lane 5). As 
negative controls, we tested ARNT and SF1 antibodies; we did not observe disruption of the rs2281721 
C allele band (Figure 2.13). These data provide evidence supporting USF1 binding to the C allele of 
rs2281721. 
To validate the USF1 binding in a native chromatin context, we performed ChIP assays in both 
HepG2 (rs2281721 genotype T/C) and Huh-7 (rs2281721 genotype C/C) cells. The ChIP assays provided 
evidence supporting USF1 binding to a 164-bp DNA region spanning rs2281721; however, this binding 
was not allele specific (Figure 2.12B). 
 
2.3.8 CEBPB binds differentially to the alleles of rs4846913 
We also observed more protein binding to the A allele than to the C allele of rs4846913 (lane 2 
versus 7, arrow, Figures 2.14A and 2.15). We observed a greater decrease in band intensity upon 
addition of 63-fold excess unlabeled rs4846913 A probe than upon addition of 63-fold excess unlabeled 
rs4846913 C probe, suggesting that competition of the lane 2 band with unlabeled rs4846913 A probe is 
more effective than competition with the unlabeled rs4846913 C probe (lane 3 versus 4). rs4846913 
overlaps CEBPB ChIP-seq peaks from ENCODE data in HepG2 cells and a predicted CEBPB binding 
motif. Incubation of the EMSA reactions with a CEBPB antibody generated a strong supershift band for 
the A allele and a detectable supershift band for the C allele (lane 5 versus 10,Figure 6A). As negative 
controls, we tested HNF4A or RXRA antibodies; we did not observe evidence of supershifts (Figure 2.13). 
To validate the differential CEBPB binding in a native chromatin context, we performed ChIP 
assays in both HepG2 (rs4846913 genotype A/C) and Huh-7 (rs4846913 genotype C/C) cells. A 120-bp 
region of DNA containing rs4846913 showed 31-fold more CEBPB binding in HepG2 cells than in Huh-7 
cells (p = 0.006; Figure 2.14B). These results are consistent with the EMSA result of increased CEBPB 
binding to rs4846913 A. 
The CEBPB ChIP-seq signal at rs4846913 was sufficiently strong to permit an analysis of allelic 
imbalance reflecting in vivo CEBPB binding. We re-aligned HepG2 CEBPB ChIP-seq reads and HepG2 
DNase-seq reads by using an allele-aware approach to avoid reference-allele bias (see Material and 
 22 
Methods). Among CEBPB reads spanning rs4846913, 57 of 78 (73%) contained the rs4846913 A allele 
(binomial p = 5.6 × 10
−5
; Figure 2.14C). Among DNase-seq reads spanning rs4846913, 31 of 83 (37%) 
contained the rs4846913 A allele (binomial p = 0.03; Figure 2.14C), suggesting that CEBPB might help 
protect the DNA sequence containing the A allele from being accessible to the DNase I enzyme. Taken 
together, the EMSA, ChIP, and allelic imbalance in ChIP-seq and DNase-seq reads all show consistent 
evidence suggesting stronger CEBPB binding to the A allele of rs4846913. 
 
2.3.9 rs2144300, rs1555290, and rs6143660 also show suggestive evidence of protein binding 
EMSAs using HepG2 nuclear lysate for the other variants in the four-variant haplotype 
(rs2144300, rs1555290, and rs6143660) showed suggestive evidence of differential allelic protein binding 
(Figures 2.16, 2.17, 2.18). The rs1555290 C probe showed a reproducible band (arrow, Figure 2.16), and 
the addition of 30-fold excess unlabeled rs1555290 C probe competed away the signal (lane 7) more 
effectively than did the addition of 30-fold excess unlabeled rs1555290 A probe (lane 8). The rs6143660 
deletion allele showed multiple protein-binding bands (lane 2, Figure 2.17) that were altered by incubation 
with FOXO3 antibody (Figure 2.19), although it is challenging to interpret results when using EMSA 
probes of different sequence lengths to compare the 21-bp-insertion and 21-bp-deletion alleles. However, 
we did not observe any disruption of the band corresponding to the rs6143660 deletion allele when we 
tested additional antibodies CEBPA, CEBPB, HR1H3, MAX, and RXRA (Figure 2.19). A weak, 
reproducible, allele-specific band for rs2144300 C was observed, but it was not fully competed away with 
excess unlabeled rs2144300 C probe (Figure 2.18). Overall, these EMSA data suggest that these other 
three variants in the haplotype might exhibit differential transcription-factor binding. 
 
2.3.10 Variants associated with GALNT2 expression 
On the basis of the location of the HDL-C-associated variants within GALNT2 intron 1, we 
hypothesized that these variants might be acting in cis to regulate GALNT2 expression. We assessed 
GALNT2 expression stratified by genotype of rs4846914 (r
2
 = 1 with rs4846913) in 50 primary human 
hepatocyte samples, and we observed a trend toward association between genotype and GALNT2 
expression (p = 0.08;  Figure 2.20). To increase the sensitivity by removing the sample-specific 
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contribution of environmental factors, we performed AEI assays in 36 human hepatocyte samples 
heterozygous for rs4846914. Of 142 variants in r
2
 > 0.2 with rs4846914 in METSIM, none are transcribed, 
so we used qPCR to measure relative allelic cDNA levels from GALNT2 pre-mRNA at rs4846914. 
Previous studies have similarly used intronic SNPs in unspliced RNA to measure allelic expression[119, 
120]. The rs4846914 A allele, which is associated with increased HDL-C, showed higher GALNT2 cDNA 
expression (p = 5.4 × 10
−7
; Figure 2.21A). When normalized to the allelic difference detected in 
heterozygous genomic DNA, the A allele of rs4846914 showed a 7.4% increase in expression. Finally, we 
examined rs4846914 in preliminary expression-quantitative-trait-locus (eQTL) data from subcutaneous 
adipose tissue from 1,381 individuals in the METSIM study (M.C. and Y.W., unpublished data) and 
observed consistent association between the rs4846914 A allele and increased expression of GALNT2 (p 
= 2.2 × 10
−14
; Figure 2.21B), but not expression of 16 other potential target genes (p > 0.05/17 = 0.003 on 
the basis of 17 tests; Figure 2.22 and Table 2.6). Conditioning on the lead eQTL variant, rs4846922, 
attenuated the association signal with GALNT2 expression (p > 0.2; Figure 2.22 and Table 2.7). 
 
2.4 Discussion 
We identified multiple functional regulatory variants that contribute to the single strong HDL-C 
GWAS signal at GALNT2. Variants rs2281721 and rs4846913, located 2 kb apart, showed strong and 
consistent allelic and haplotype differences in enhancer activity and exhibited transcription-factor binding 
of USF1 and CEBPB, respectively. Variants rs2144300 and rs6143660 showed moderate effects on 
transcriptional activity and suggestive allelic differences in binding of nuclear proteins, although we did 
not confirm the identity of these potential regulatory proteins. In addition, rs1555290, in moderate LD (r
2
 = 
0.26) with the GWAS variants, also showed suggestive haplotype differences in enhancer activity and 
allelic differences in binding of a nuclear protein. For all of these variants, the alleles associated with 
increased HDL-C showed higher transcriptional activity in reporter assays and were associated with 
higher expression ofGALNT2 in human hepatocyte and human subcutaneous adipose tissue samples. 
By testing all variants in strong LD (r
2
 > 0.7) with lead HDL-C GWAS variant rs4846914 in luciferase 
reporter assays in both forward and reverse orientations, we identified the most likely functional 
regulatory candidates. Although we used a threshold of r
2
 > 0.7 to identify the most likely functional 
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candidates, we cannot rule out the possibility that we could have missed additional functional variants in 
weaker LD with the lead HDL-C-associated variant. Of 14 DNA segments tested, we observed that a 
segment containing four variants and a separate segment containing rs2281721 showed up to 49-fold 
and 75-fold, respectively, more enhancer activity than did the empty-vector control. One additional 
element containing one SNP, rs10864726, showed more-moderate allelic differences in enhancer activity 
(2.5-fold [T allele] versus 1.8-fold [C allele] more than the empty vector, p = 0.003) in only the forward 
orientation (Figure 2.23). Compared to a vector control, the remaining 11 segments did not exhibit 
enhancer activity in both orientations, nor did they exhibit significant differences between alleles. These 
11 segments included one of the lead GWAS SNPs, rs4846914, and the lead SNP from our fine-mapping 
analysis, rs17315646. These two SNPs are located in regions containing H3K4me1, H3K4me2, 
H3K4me3, H3K9ac, and H3K27ac peaks in HepG2 cells and H3K4me1 peaks in adult liver cells, 
demonstrating that not all GWAS variants located in regulatory elements contribute to regulatory function. 
Open-chromatin peaks and histone-modification and transcription-factor ChIP-seq data in liver 
cell types partially predicted the variants that showed regulatory activity. Variants rs4846913, rs2144300, 
rs1555290, and rs6143660 overlapped the most peaks (≥22 each) of any candidate variant, but 
rs2281721 did not overlap any DNase or FAIRE peaks; instead, it overlapped only four histone-
modification peaks (H3K4me1, H3K4me2, H3K9ac, and H3K27ac) and one transcription-factor ChIP-seq 
peak (USF1). We compared our results to the Probabilistic Identification of Causal SNPs (PICS) 
algorithm’s[121] prediction of candidate causal variants in this region. The variants that overlapped the 
most marks of open chromatin and histone modification in liver cell types (rs4846914, rs10127775, 
rs4846913, rs2144300, rs17315646, and rs10864726) showed the highest prediction scores, whereas the 
remaining 19 variants (including rs2281721) showed a prediction score of 0. Thus, testing many 
candidate variants in experimental assays was necessary for identifying all variants that showed strong 
allelic differences in enhancer activity. We also conclude that testing all candidate variants in strong LD in 
combination with regulatory datasets provides the best chance of identifying regulatory variants that 
exhibit allelic differences in enhancer activity. 
One or more of these regulatory variants might also influence gene expression in other cell types. 
In addition to being present in HepG2 cells, rs4846913, rs2144300, rs1555290, rs6143660, and 
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rs2281721 are also located within predicted ChromHMM[103] strong enhancer chromatin states in K562 
leukemia cells from ENCODE data[72] and ChromHMM active enhancer chromatin states in multiple cell 
types and tissues from Roadmap Epigenomics data[73] including adipose nuclei, CD34 cells, brain, 
pancreas, and skeletal muscle (Figure 2.3). 
One or more of the 21 candidate variants that did not show haplotype or allelic differences in 
enhancer activity in both orientations, especially those variants tested individually in smaller segments, 
might also contribute to the GALNT2 regulatory mechanism. Testing smaller segments (∼100–200 bp) in 
reporter assays can help with focusing on individual variants; however, these segments might fail to 
capture full regulatory elements. Testing larger segments can be beneficial because they could 
encompass a regulatory element, although segment size must be balanced with the fact that larger 
elements might contain both enhancer and repressor regions and mask modest allelic effects. 
The observation that the 780-bp segment showed similar haplotype differences in enhancer 
activity in both a luciferase vector with a minimal promoter and a promoterless luciferase vector further 
confirms that rs4846913, rs2144300, rs1555290, and rs6143660 are located within a regulatory element 
that drives expression. We did not find annotated evidence of an alternative promoter or alternative 
splicing in this region; however, we cannot rule out alternate mechanisms. Using qRT-PCR and strand-
specific primers, we detected hepatocyte and HepG2 RNA transcribed from both strands within GALNT2 
intron 1 (T.R., unpublished data). This result is not unexpected, given that transcription initiation has been 
found to occur in both directions at both promoters and enhancers[122].  
The functional regulatory variants at this locus might bind multiple transcription factors and act 
together in a complex to influence transcriptional enhancer activity. Increased binding of CEBPB to the 
rs4846913 A allele, associated with increased HDL-C, is consistent with the fact that CEBPB acts as a 
transcriptional activator[123]. CEBPB is a CCAAT/enhancer binding transcription factor that plays diverse 
roles in cell proliferation, development, adipocyte differentiation, immune response, and liver gene 
expression[124-128]. Knockdown of CEBPB (71% of negative control) by siRNA in HepG2 cells resulted 
in a modest 22% decrease in GALNT2 expression (p = 0.058; Figure 2.24), suggesting that other 
transcription factors within a complex might bind to rs4846913 and be sufficient to preserve substantial 
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enhancer activity and GALNT2 expression in HepG2 cells. Nonetheless, our data suggest that differential 
binding of CEBPB to rs4846913 is one potential molecular mechanism underlying the HDL-C association. 
The other candidate regulatory variants, rs2281721, rs2144300, rs1555290, and rs6143660, 
might also bind one or more transcription factors. Binding of USF1 to rs2281721 was allele specific in 
EMSAs; however, ChIP assays in HepG2 (C/T at rs2281721) and Huh-7 (C/C at rs2281721) cells suggest 
that USF1 binds to both alleles of rs2281721 in a native chromatin context. Therefore, USF1 might not 
drive the allelic differences observed in EMSAs and in HepG2 and Huh-7 cell transcriptional reporter 
assays. USF1 is an upstream stimulatory factor and has been shown to bind to lipid- and glucose-
metabolism-related genes[129-131] and affect cholesterol homeostasis, insulin sensitivity, and body-fat 
mass[132]. The other three potential regulatory variants, rs2144300, rs1555290, and rs6143660, each 
overlap ≥13 transcription-factor ChIP-seq peaks in HepG2 cells. Future experiments will be valuable for 
confirming the role of CEBPB and USF1 in GALNT2 expression, identifying other transcription factors 
contributing to the haplotype differences in transcriptional enhancer activity, detecting physical 
interactions of this enhancer region, and fully characterizing this complex molecular mechanism at 
GALNT2. 
The transcriptional reporter assays all exhibit the same direction of effect; alleles associated with 
increased HDL-C are also associated with increased enhancer activity. In the assay of liver AEI 
(Figure 2.21A) and the study on adipose eQTLs (Figure 2.21B and Figure 2.22), the rs4846914 A allele 
associated with increased HDL-C was associated with higher GALNT2 expression. Although the HDL-C 
GWAS variants were not associated with GALNT2 expression in an eQTL dataset of more than 400 liver 
samples (p < 3.95 × 10
−8
)[133] or in our eQTL analysis of primary hepatocyte samples from 50 individuals 
(Figure 2.20), significant associations were previously observed[134] in 146 human liver biopsy samples 
(p = 0.002) and 105 carotid-atherosclerotic-plaque biopsy samples (p = 0.001), consistent with our 
observed direction of effect. The evidence of variant association with the level of GALNT2 expression in 
both liver and adipose tissue is consistent with the frequent observation that eQTLs are shared across 
multiple tissues[135]. This direction of effect is opposite to the effect on HDL-C of a previous study that 
used adeno-associated viral vectors to overexpress and knock down mouse Galnt2[87] and a study that 
observed a rare GALNT2 missense variant in humans[101]. Notably, our observed direction of effect of 
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the human GWAS variants is consistent with recent unpublished studies demonstrating that total loss of 
function of GALNT2 in humans, mice, rats, and cynomolgus monkeys consistently results in lower HDL-C 
(S. Khetarpal, D. Rader, personal communication). GALNT2 remains a likely candidate gene, considering 
the association between the GWAS variants and GALNT2 expression, but not expression of 16 other 
potential target genes within 1 Mb in samples of subcutaneous adipose tissue. However, the regulatory 
variants we identified might also act to increase expression of other nearby genes that might contribute to 
the HDL-C association signal. Identification of the functional variants responsible for the human GWAS 
signal can provide further understanding of the direction of effect in humans and lead to a greater insight 
into the molecular mechanisms of how these variants might influence gene expression and function. 
In the METSIM cohort, the studied variants were most strongly associated with traits correlated 
with total cholesterol in medium HDL, including cholesterol esters in medium HDL (r
2
 = 1.0), 
concentrations of medium HDL particles (>0.9), phospholipids in medium HDL (>0.9), and free cholesterol 
in medium HDL (>0.9). Sub-phenotype associations can provide additional insight into the function of 
GWAS loci[136]. GALNT2 might act during specific steps of HDL-particle formation or remodeling by 
directly glycosylating lipid modifiers or enzymes, such as ANGPTL3[100] or LIPG, an enzyme that has 
been shown to hydrolyze phospholipids in HDL[137, 138] and remodel HDL particles[138]. More work is 
necessary for determining the mechanism(s) by which GALNT2 might influence the size of HDL particles. 
Overall, this study demonstrates multiple lines of evidence suggesting that at least two regulatory 
variants might act to regulate expression of GALNT2, a gene involved in HDL-C metabolism (Figure 2.25). 
The eQTL and AEI data clarify the direction of effect by which the GWAS variants act. Our study joins a 
growing set of studies that implicate multiple functional regulatory variants at a GWAS locus[139, 
140], highlighting the complexity of molecular mechanisms underlying GWAS loci, and emphasizes that 
multiple common functional regulatory variants might work in concert. 
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Figure 2.1 Non-coding variants at GALNT2 are associated with total cholesterol in medium HDL in 
the METSIM study 
The entire initial association signal (upper panel) was reduced after conditioning on lead SNP rs17315646 
(lower panel). Circles represent genotyped and imputed DNA variants and their LD r2 values with 
rs17315646 in the METSIM study (2,079 variants are shown). Chromosome coordinates correspond to 
UCSC Genome Browser build hg19. The left y axis indicates the −log10(p value), the right y axis indicates 
the recombination rate (cM/Mb), and the x axis indicates position on chromosome 1 (Mb). 
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Figure 2.2 HDL-C-associated variants overlap open chromatin and histone modifications 
indicating potential regulatory regions in GALNT2 intron 1 
A 13.7-kb region includes all 24 variants in strong LD (r
2
 > 0.7) with the HDL-C-associated index SNP 
rs4846914 (25 total candidate variants). Selected Human Epigenome Atlas and ENCODE open-
chromatin and histone-modification tracks are shown. Rectangular bars represent elements containing 
the variant(s) that were tested in luciferase reporter assays. 
 
 
 
 30 
 
Figure 2.3 HDL-C associated variants overlap open chromatin, histone modifications, and 
predicted enhancer and transcribed chromatin states in liver cell types identifying potential 
regulatory regions in GALNT2 intron 1 
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Figure 2.3 HDL-C associated variants overlap open chromatin, histone modifications, and 
predicted enhancer and transcribed chromatin states in liver cell types identifying potential 
regulatory regions in GALNT2 intron 1 
A 13.7-kb region includes all 24 variants in strong linkage disequilibrium (r
2
>.7) with the HDL-C-
associated index SNP rs4846914 (25 total candidate variants). Selected Roadmap Epigenomics Human 
Epigenome Atlas histone modification and chromatin state segmentation tracks and ENCODE open 
chromatin, histone modification and ChromHMM chromatin state tracks are shown. Rectangular bars 
represent elements containing the variant(s) that were tested in luciferase reporter assays. GM12878, B-
lymphocyte, lymphoblastoid cells; H1-hESC, embryonic stem cells; K562, leukemia cell line; HMEC, 
human mammary epithelial cells; HSMM, human skeletal muscle myoblasts; HUVEC, human umbilical 
vein endothelial cells; NHEK, epidermal keratinocytes; NHLF, lung fibroblasts, Brain AG, angular gyrus; 
Brain AC, anterior caudate; Brain CG, cingulate gyrus; Brain ITL, inferior temporal lobe; Brain MFL, mid-
frontal lobe; Brain SN, substantia nigra; CD34C, CD34 cultured cells. Yellow and orange ChromHMM 
regions indicate weak and active enhancers, respectively, white indicates quiescent/lowly expressed 
regions, red indicates promoter regions, green indicates transcribed regions, and blue indicates insulator 
regions. 
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Figure 2.4 Two of 14 elements containing variants in strong linkage disequilibrium (r
2 
> 0.7) with 
rs4846914 show allelic or haplotype differences in transcriptional enhancer activity in both 
orientations 
Luciferase activity of DNA segments containing one to four variants cloned upstream of a minimal 
promoter luciferase vector and transfected into HepG2 cells. Black bars indicate luciferase activity of 
segments containing the allele/haplotype associated with increased HDL-C, and dark gray bars indicate 
segments with the other allele/haplotype, both cloned in the forward orientation. Light gray bars represent 
luciferase activity of segments containing the allele/haplotype associated with HDL-C, and white bars 
indicate fragments containing the other allele/haplotype, both cloned in the reverse orientation. Luciferase 
activity is shown normalized to an empty vector control (EV). Error bars represent standard deviation of 2-
6 independent clones per allele/haplotype, except for 2-bp indel rs34966440, which was tested with 1-3 
independent clones in the reverse orientation. The element containing rs4846922 (LD r
2 
> 0.7 with 
rs4846914) contained an additional SNP, rs4846923 (r
2 
> 0.6 with rs4846914). 
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Figure 2.5 Twenty-one GALNT2 intronic variants tested in reporter assays do not exhibit allelic or 
haplotype differences in transcriptional enhancer activity in both orientations 
Luciferase activity of DNA segments containing one to four variants cloned upstream of a minimal 
promoter luciferase vector and transfected into HepG2 cells. These 11 segments did not show allelic 
differences in enhancer activity (<1.5-fold) in both orientations compared to a vector control. Black bars 
indicate luciferase activity of segments containing the allele/haplotype associated with increased HDL-C, 
and dark gray bars indicate segments with the other allele/haplotype, both cloned in the forward 
orientation. Light gray bars represent luciferase activity of segments containing the allele/haplotype 
associated with HDL-C, and white bars indicate fragments containing the other allele/haplotype, both 
cloned in the reverse orientation. Luciferase activity is shown normalized to an empty vector control (EV). 
Error bars represent standard deviation of 2-6 independent clones per allele/haplotype, except for 2-bp 
indel rs34966440, which was tested with 1-3 independent clones in the reverse orientation. The element 
containing rs4846922 (LD r
2 
> 0.7 with rs4846914) contained an additional SNP, rs4846923 (r
2 
> 0.6 with 
rs4846914). 
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Figure 2.6 Haplotype and allelic differences in transcriptional activity at the GALNT2 locus 
Segments containing each haplotype or allele were cloned into a pGL4.23 luciferase reporter vector 
upstream of the minimal promoter in both orientations. The vectors were transfected into HepG2 cells, 
and luciferase expression normalized to that of an empty vector control is shown. Error bars represent the 
pairwise SD of three to six independent clones per allele or haplotype (t tests). Abbreviations are as 
follows: P, promoter; and luc, luciferase. 
A Luciferase activity of 154-bp DNA segments containing rs2281721 alleles. 
B Luciferase activity of 780-bp DNA segments of two different haplotypes. The haplotypes contained 
three candidate variants in strong LD: rs4846913, rs2144300, and 21-bp indel, rs6143660. An additional 
variant, rs1555290, was detected in the segment, as shown in Figures 2.8 and 2.9. 
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Figure 2.7 Haplotype and allelic differences in transcriptional activity at the GALNT2 locus are 
consistent in Huh-7 cells 
Segments containing each haplotype/allele were cloned into a pGL4.23 luciferase reporter vector 
upstream of the minimal promoter in both orientations. The vectors were transfected into Huh-7 cells, and 
luciferase expression is shown normalized to an empty vector control. Error bars represent pairwise 
standard deviation of 3-5 independent clones per allele/haplotype (t-tests). P, promoter; luc, luciferase 
gene. 
A Luciferase activity of 154-bp DNA segments containing rs2281721 alleles. 
B Luciferase activity of 780-bp DNA segments of 2 different haplotypes. The haplotypes contained three 
candidate variants in strong LD, rs4846913, rs2144300, and 21-bp indel, rs6143660. Luciferase activity 
measurements were performed on the same day as the site-directed haplotypes and are also shown in 
Figure 2.9. 
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Figure 2.8 Haplotype variants act together to increase transcriptional activity 
Additional haplotypes were created by site-directed mutagenesis of haplotypes cloned into a pGL4.23 
luciferase vector in the forward orientation. All constructs were transfected separately into HepG2 cells, 
and this experiment was performed separately from the experiment presented in Figure 2.6. Luciferase 
activity was measured and normalized to that of an empty vector control. Error bars represent the 
pairwise SD of three to four independent clones per haplotype (ANOVA and Tukey’s post hoc tests). 
Abbreviations are as follows: P, promoter; and luc, luciferase. 
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Figure 2.9 Haplotype variants act together to increase transcriptional activity in Huh-7 cells 
Additional haplotypes were created by site-directed mutagenesis of haplotypes cloned into pGL4.23 
luciferase vector in the forward orientation. All constructs were transfected separately into Huh-7 cells. 
Luciferase activity was measured and normalized to empty vector control. Error bars represent standard 
deviation of 3-4 independent clones per haplotype (ANOVA and Tukey post-hoc tests). P, promoter; luc, 
luciferase. All haplotypes are present as in Figure 2.8 except for CTA-. 
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Figure 2.10 The 780-bp segment shows haplotype differences in enhancer activity in a 
promoterless vector 
Luciferase activity of 780-bp DNA segments in 3 different allelic combinations cloned upstream of a 
promoterless pGL4.10 luciferase reporter after transfection into HepG2 cells. The segments contained 
two SNPs, rs4846913, rs2144300, and a 21-bp indel, rs6143660 in strong pairwise LD, and an additional 
SNP, rs1555290, in moderate LD (r
2 
= 0.2) with the HDL-C-associated variants. Luciferase activity is 
shown normalized to an empty vector control. Error bars represent standard deviation of 4-7 independent 
clones per haplotype. P, promoter; luc, luciferase. 
 39 
 
Figure 2.11 SNPs rs4846913, rs2144300, rs1555290 and 21-bp indel rs6143660 do not show allelic 
differences in enhancer activity when cloned and tested as separate segments in luciferase 
reporter assays 
Luciferase activity of 120-bp DNA segments containing rs4846913 A or C alleles, 201-bp DNA segments 
containing rs2144300 T or C alleles, 121–bp segments containing rs1555290 A or C alleles, and 173-bp 
DNA segments containing a 21-bp deletion or 21-bp insertion (rs6143660). Error bars represent standard 
deviation of 2-5 independent clones per haplotype. Luciferase activity is shown normalized to an empty 
vector control. P, promoter; luc, luciferase. 
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Figure 2.12 The rs2281721 C Allele shows binding to USF1 
A EMSAs with biotin-labeled probes containing either the T or C allele of rs2281721 and incubated with 
5 μg HepG2 nuclear lysate. The arrow indicates an allele-specific band (lanes 2 and 7), and the asterisk 
indicates the C-allele-specific band that was disrupted upon incubation with USF1 antibody (lane 5). For 
competition reactions, 40-fold excess unlabeled probe was added. 
B ChIP experiments were performed in HepG2 cells (T/C at rs2281721) and Huh-7 cells (C/C at 
rs2281721) with USF1 antibody or rabbit IgG control, and a 164-bp DNA region containing rs2281721 
was amplified via qPCR and quantified with a standard curve. Results are shown as percentages of input 
DNA. Error bars represent the SEM of two independent USF1 and IgG ChIP experiments each in HepG2 
and Huh-7 cells. 
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Figure 2.13 Transcription factors not bound to rs2281721 or rs4846913 
To confirm specificity of USF1 binding to rs2281721 and CEBPB binding to rs4846913, additional 
antibodies were tested in EMSAs as negative controls. Neither ARNT nor SF1 bind to the alleles of 
rs2281721, and neither HNF4A nor RXRA bind to the alleles of rs4846913.   
A Probes containing alleles of rs2281721 were incubated with 6 μg HepG2 nuclear lysate and 4 μg USF1 
antibody (lanes 3 and 8), ARNT antibody (lanes 4 and 9) or SF1 antibody (lanes 5 and 10). For 
competition reactions, 119-fold excess unlabeled probe was added. 
B Probes containing alleles of rs4846913 were incubated with 6 μg HepG2 nuclear lysate and 4 μg 
HNF4A antibody (lanes 4 and 7). For competition reactions, 63-fold excess unlabeled probe was added. 
C Probes containing alleles of rs4846913 were incubated with 3.5 μg HepG2 nuclear lysate and 4 μg 
RXRA antibody (lanes 3 and 6). For competition reactions, 63-fold excess unlabeled probe was added. 
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Figure 2.14 CEBPB binds differentially to the alleles of rs4846913 
A EMSAs with biotin-labeled probes containing either the A or C allele of rs4846913 and incubated with 
6 μg HepG2 nuclear lysate. The arrow indicates increased protein binding to the A allele (lanes 2 versus 
7). The asterisk indicates evidence of a CEBPB supershift. For competition reactions, 63-fold excess 
unlabeled probe was added. 
B ChIP experiments were performed in HepG2 cells (A/C at rs4846913) and Huh-7 cells (C/C at 
rs4846913) with CEBPB antibody or rabbit IgG control, and a 120-bp DNA region containing rs4846913 
was amplified via qPCR and quantified with a standard curve. Results are shown as percentages of input 
DNA. Error bars represent the SEM of two independent CEBPB and IgG ChIP experiments each in 
HepG2 and Huh-7 cells. 
C CEBPB ChIP-seq reads and DNase-seq reads from ENCODE data in a region containing rs4846913 
(UCSC Genome Browser hg19 chromosome coordinates). Blue indicates reads that contain the A allele 
of rs4846913, red indicates reads that contain the C allele of rs4846913, and gray indicates reads that do 
not overlap rs4846913 in the peak. 
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Figure 2.15 The alleles of rs4846913 show consistent allelic differences in binding 
Electrophoretic mobility shift assays with biotin-labeled probes containing either the A or C allele of 
rs4846913. Supershift reactions were incubated with a different lot number of CEBPB antibody, resulting 
in a slightly different supershift band compared to Figure 2.14. Probes were incubated with 5 μg HepG2 
nuclear lysate. The arrows indicate allele-specific protein binding to the A allele, which is competed away 
effectively by 40-fold excess competitor DNA containing the A allele (lane 3) compared to excess 
competitor containing the C allele (lane 4). An additional allele-specific band was present compared to 
Figure 2.14 (indicated by the lower arrow). The asterisk indicates a supershift upon incubation with a 
CEBPB antibody. 
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Figure 2.16 The alleles at rs1555290 exhibit allele-specific protein binding 
Electrophoretic mobility shift assays with biotin-labeled probes containing either the A or C allele of 
rs1555290. Probes were incubated with HepG2 nuclear lysate. The arrow indicates allele-specific protein 
binding to the C allele, which was reproducible and observed on at least 3 separate days. For competition 
reactions, 30-fold excess unlabeled probe was added.  
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Figure 2.17 DNA sequence containing the 21-bp rs6143660 deletion allele shows evidence of 
protein binding 
A Electrophoretic mobility shift assays with biotin-labeled probes containing a 18-bp DNA sequence 
flanking the 21-bp deletion. Probes were incubated with HepG2 nuclear lysate. Arrows indicate specific 
bands that are competed away by excess unlabeled competitor. For competition reactions, 300-fold 
excess unlabeled probe was added. 
B EMSAs with biotin-labeled probes containing the alternate insertion allele of rs6143600, a 39-bp DNA 
sequence containing the 21-bp insertion and 9 bp of DNA sequence flanking either side. For competition 
reactions, 150-fold excess unlabeled probe was added. 
C Schematic of labeled DNA EMSA probes containing the 21-bp rs6143660 deletion and insertion alleles. 
The deletion allele probes contain 9 bp of flanking DNA sequence (total 18 bp) and the insertion allele 
probes contain the 21-bp insertion sequence plus 9 bp of flanking DNA sequence on either side (total 39 
bp). 
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Figure 2.18 The alleles at rs2144300 show suggestive differential protein binding 
Electrophoretic mobility shift assays with biotin-labeled probes containing either the T or C allele of 
rs2144300. Probes were incubated with HepG2 nuclear lysate. The arrow indicates allele-specific protein 
binding to the C allele, however, the band is not competed away upon addition of excess unlabeled 
rs2144300-C probe (lane 7). For competition reactions, 240-fold excess unlabeled probe was added. To 
resolve allele-specific bands, the unbound probes were run off the gel and were not transferred to the 
membrane for visualization. 
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Figure 2.19 Specificity of FOXO3 binding to the deletion allele of rs6143660 
To confirm specificity of FOXO3 binding to the deletion allele of rs6143660, additional antibodies were 
tested in EMSAs as negative controls. Biotin-labeled probes containing a 18-bp DNA sequence flanking 
the 21-bp deletion were incubated with HepG2 nuclear lysate. Arrows indicate specific bands that are 
competed away by excess unlabeled competitor and the asterisk indicates the band that is disrupted 
upon incubation with FOXO3 antibody (lane 5). For competition reactions, 200-fold excess unlabeled 
probe containing the 18-bp sequence (lane 3) or the 21-bp insertion sequence (lane 4) was added. 
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Figure 2.20 GALNT2 expression in human hepatocytes from 50 individuals  
GALNT2 mRNA was measured by quantitative PCR and normalized to a housekeeping gene (Beta-2 
microglobulin). Normalized GALNT2 expression was then grouped based on genotype at the lead HDL-C-
associated SNP rs4846914. GALNT2 expression values were natural log transformed to obtain an 
approximate normal distribution. Horizontal lines within the boxes represent the median expression 
values, and whiskers represent the minimum and maximum expression values observed for each 
genotype. 
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Figure 2.21 The rs4846914 A Allele associated with increased HDL-C is associated with 
higher GALNT2 RNA expression in primary human hepatocytes and subcutaneous adipose tissue 
A AEI assays were performed in primary human hepatocytes from 36 individuals heterozygous for the 
intronic HDL-C-associated lead SNP rs4846914 (p = 5.4 × 10
−7
). rs4846914 was used as a proxy for SNP 
rs4846913. DNA results from genomic DNA are shown as a control, and cDNA results in this intronic 
region represent pre-mRNA. 
B eQTL queries were performed for the noncoding GALNT2 variants and GALNT2 expression in 
subcutaneous adipose tissue samples from 1,381 individuals from the METSIM study. Circles represent 
genotyped and imputed DNA variants and the LD r
2
 values with lead eQTL variant rs4846922. LD was 
calculated from METSIM genotypes imputed from 1000 Genomes Phase 1 EUR dataset. Chromosome 
coordinates correspond to UCSC Genome Browser build hg19. The left y axis indicates the −log10(p 
value), the right y axis indicates the recombination rate (cM/Mb), and the x axis indicates position on 
chromosome 1 (Mb). 
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Figure 2.22 Non-coding variants at GALNT2 are associated with GALNT2 expression in adipose 
tissue samples from 1381 individuals from the METSIM study 
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Figure 2.22 Non-coding variants at GALNT2 are associated with GALNT2 expression in adipose 
tissue samples from 1381 individuals from the METSIM study 
The entire association signal (upper panel) is reduced after conditioning on the lead GWAS HDL-C-
associated variant rs4846914 (middle panel). The association signal is also diminished after conditioning 
on the lead eQTL SNP, rs4846922 (lower panel). rs4846922 is in strong LD (r
2 
= 0.82) with rs4846914. 
LD was calculated from METSIM genotypes imputed from 1000 Genomes Phase I EUR. Association plot 
in the upper panel is also shown in Figure 2.21B. The left Y-axis indicates the –log10(p-value), the right Y-
axis indicates the recombination rate (cM/Mb) and the X-axis indicates position on chromosome 1 (Mb).  
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Figure 2.23 An additional SNP, rs10864726, shows modest allelic differences in enhancer activity 
in the forward but not reverse orientation 
Luciferase activity of 204-bp DNA segments containing rs10864726 in 2 different allelic combinations 
cloned into a pGL4.23 luciferase reporter upstream of the minimal promoter in both orientations. Error 
bars represent standard deviation of 2-5 independent clones per haplotype. P, promoter; luc, luciferase. 
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Figure 2.24 siRNA-mediated knockdown of CEBPB in HepG2 cells results in a modest decrease in 
GALNT2 expression 
HepG2 cells were untreated, treated with 50 nM negative control siRNA or treated with 50 nM CEBPB 
siRNA in triplicate, and RNA was harvested 48 hours after transfection of siRNAs. Expression of CEBPB 
and GALNT2 were measured by qPCR and normalized to B2M expression. The y-axes show normalized 
CEBPB or GALNT2 expression in untreated or CEBPB siRNA-treated cells as a percent of normalized 
CEBPB or GALNT2 expression in negative control siRNA-treated cells. Error bars indicate standard error 
of the mean of triplicate samples of one experiment. 
A % gene expression of CEBPB.  
B % gene expression of GALNT2.  
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Figure 2.25 Multiple HDL-C-associated variants bind transcription factors at GALNT2 
Arrows indicate the transcription start site (TSS) of the GALNT2 gene. Ovals represent proteins that are 
bound to DNA variant alleles. rs4846913 and rs2281721, shown in black, demonstrated allelic differences 
in enhancer activity. rs4846913 showed greater CEBPB binding to the A allele in EMSAs and ChIP 
assays. rs2281721 showed greater USF1 binding to the C allele in EMSAs and USF1 binding to both 
alleles in ChIP assays. rs2144300, shown in black, showed allelic differences in enhancer reporter activity 
as part of a haplotype and suggestive differences in protein binding. rs1555290 and rs6143660, shown in 
gray, showed allelic differences in protein binding in EMSAs. The alleles that showed stronger enhancer 
reporter activity are the alleles that showed higher GALNT2 expression in liver and adipose tissues. 
These alleles are also associated with increased HDL-C. 
 
 
 
 
 
 
 
 
 
 55 
Lipoprotein Subclass Name  Particle diameter (nm) 
Chylomicrons and extremely large VLDL particles 75 nm and above 
very large VLDL 64 nm 
large VLDL 53.6 nm 
medium VLDL 44.5 nm 
small VLDL 36.8 nm 
very small VLDL 31.3 nm 
IDL 28.6 nm 
large LDL 25.5 nm 
medium LDL 23.0 nm 
small LDL 18.7 nm 
very large HDL 14.3 nm 
large HDL 12.1 nm 
medium HDL 10.9 nm 
small HDL 8.7 nm 
 
Table 2.1 Definitions of lipoprotein subclass measurements for association analyses in the 
METSIM study 
VLDL, very-low-density lipoprotein; IDL, intermediate-density lipoprotein; LDL, low-density lipoprotein; 
HDL, high-density lipoprotein 
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Primer 
sequences 
used to 
amplify DNA 
for luciferase 
reporter 
assays 
Sequence 5’-3’ Chromosome 1 position (hg19) 
rs4631704_F 
rs4631704_R 
GCATTAAGAAGCCAGGTCCA 
AGAACAGTGCCACCATCCTC 
230293458 
230293625 
rs4846913-
rs2144300-
rs1555290-
rs6143660_F 
rs4846913-
rs2144300-
rs1555290-
rs6143660_R 
GGCTCTGGCAAAGTGTCTTG 
 
TGAATTTCTCCGGTTGACCT 
230294386 
 
230295165 
rs17315646-
rs4846914-
rs10127775_F 
rs17315646-
rs4846914-
rs10127775_R 
TTAGTTGAGGATCAGATGTGTCA 
 
TCAGTGAGCAGAAACTAAGGACA 
230295248 
 
230295812 
rs10864726_F 
rs10864726_R 
GCGAGAGTGAGCCTTAGGAA 
GGGTGGTCTCAAACTCCTGA 
230296062 
230296265 
rs2281719-
rs2281718-
rs10864727_F 
rs2281719-
rs2281718-
rs10864727_R 
TTCATCTGTGAAATGGATATGATG 
 
GCTGGGAGACTTAAAGGAAGG 
230297453 
 
230297964 
rs2281721_F 
rs2281721_R 
CAGGGCAGCATTCTAAGAGG 
TATTTCTTTGCCACGTCTGC 
230297074 
230297227 
rs10779835_F 
rs10779835_R 
ACGTAACTGCAATCGCACAC 
GTACGGGCAATCACACACAC 
230299854 
230300062 
rs11122450_F 
rs11122450_R 
ATGGAGTCTGGGCTTTGATG 
CAAAGGATTTGTGCAGAGGA 
230301742 
230301850 
rs11122453-
rs1546954_F 
rs11122453-
rs1546954_R 
GCTCCACTGTGGCCCTTG 
AACACTTGCTCCGAGTCCAC 
230303544 
230303893 
rs34966440_F 
rs34966440_R 
GTGGACTCGGAGCAAGTGTT 
CCATTCCTGAAGGCAAGAAC 
230303874 
230304003 
rs11122454-
rs4846921_F 
rs11122454-
rs4846921_R 
AAAGGACCTGCTGTTCTTGC 
AAGGGAAAGCAACTACACTGAAA 
230303972 
230304392 
rs10864728-
rs11122455-
rs10489615-
rs1321257_F 
rs10864728-
rs11122455-
rs10489615-
rs1321257_R 
TTGGGAGAGGAAGACCACAG 
 
TCATCCTGCACATTGATTCC 
230304838 
 
230305341 
 57 
rs11122456_F 
rs11122456_R 
GCCTTGGGAAATCCAAAACT 
GTGCCCCATGTAGCAGAAGT 
230305793 
230306034 
rs4846922-
rs4846923_F 
rs4846922-
rs4846923_R 
AAATTTCTGGCAACCTGTTTTT 
CCGAAAATACCATCTGAATGA 
230307110 
230307260 
rs4846913_F 
rs4846913_R 
ATGCCGCTTTGGATTTCAGT 
CATCCAAAAGCAGTGTCAGC 
230294687 
230294806 
rs2144300_F 
rs2144300_R 
GCTGACACTGCTTTTGGATG 
ACCAAAACCCTGTCAATTCC 
230294787 
230294987 
rs1555290_F 
rs1555290_R 
CACCCTTTGCTGTTGATGTG 
CCTTCGTGTGCAAAGATGAG 
230294932 
230295053 
rs6143660_F 
rs6143600_R 
ATTGCTCCTTTCTCCGCAAT 
TGAATTTCTCCGGTTGACCT 
230294993 
230295165 
 
Primer sequences for site-
directed mutagenesis of 
780-bp element  
 
CTA-_F 
CTA-_R 
CTTTGGATTTCAGTGGCCTCTGCAGC 
TGATGTAAGAATAATAAATTGCTGCA 
ACA-_F 
ACA-_R 
AAAGGACGCTGTACCCCTGCCCTATT 
CAGCCAATAGGGCAGGGGTACAGCG 
CCA-_F 
CCA-_R 
CTTTGGATTTCAGTGGCCTCTGCAGC 
TGATGTAAGAATAATAAATTGCTGCA 
CCC-_F 
CCC-_R 
ATTGACAGGGTTTTGGTCCATGATTG 
GGAGAAAGGAGCAATCATGGACCAAA 
Probe sequences for 
electrophoretic mobility 
shift assays 
 
rs4846913_Aforward 
rs4846913_Areverse 
TGGCCTCTGAAGCAATTTA 
TAAATTGCTTCAGAGGCCA 
rs4846913_Cforward 
rs4846913_Creverse 
TGGCCTCTGCAGCAATTTA 
TAAATTGCTGCAGAGGCCA 
rs2144300_Tforward 
rs2144300_Treverse 
CGCTGTACCTCTGCCCTAT 
ATAGGGCAGAGGTACAGCG 
rs2144300_Cforward 
rs2144300_Creverse 
CGCTGTACCCCTGCCCTAT 
ATAGGGCAGGGGTACAGCG 
rs1555290_Aforward 
rs1555290_Areverse 
GTTTTGGTCAATGATTGCT 
AGCAATCATTGACCAAAAC 
rs1555290_Cforward 
rs1555290_Creverse 
GTTTTGGTCCATGATTGCT 
AGCAATCATGGACCAAAAC 
rs2281721_Tforward 
rs2281721_Treverse 
TCCTTGCCTTGTGGTTGCT 
AGCAACCACAAGGCAAGGA 
rs2281721_Cforward 
rs2281721_Creverse 
TCCTTGCCTCGTGGTTGCT 
AGCAACCACGAGGCAAGGA 
rs6143660_deletionforward 
rs6143660_deletionreverse 
TTTTTCTCTGAGTTTATT 
AATAAACTCAGAGAAAAA 
rs6143660_insertionforward 
rs6143660_insertionreverse 
TTTTTCTCTTAAAGTGTTCAGCACTCCCCTGAGTTTATT 
AATAAACTCAGGGGAGTGCTGAACACTTTAAGAGAAAAA 
Primer sequences for 
CEBPB ChIP assay 
amplifying rs4846913 region 
Sequence 5’-3’ 
rs4846913_forward 
rs4846913_reverse 
ATGCCGCTTTGGATTTCAGT 
CATCCAAAAGCAGTGTCAGC 
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Primer sequences for USF1 
ChIP assay amplifying 
rs2281721 region 
Sequence 5’-3’ 
rs2281721_forward 
rs2281721_reverse 
GGTCTCAGGGCAGCATTCTA 
GGCCATATTTCTTTGCCACG 
Primer sequences for 
GALNT2 mRNA expression 
assays 
Sequence 5’-3’ 
GALNT2 forward 
GALNT2 reverse 
AAGGAGAAGTCGGTGAAGCA 
TTGAGCGTGAACTTCCACTG 
B2M forward 
B2M reverse 
TGTCTGGGTTTCATCCATCCGACA 
TCACACGGCAGGCATACTCATCTT 
Primer sequences for 
siRNA-mediated CEBPB 
knockdown experiments 
Sequence 5’-3’ 
CEBPB forward 
CEBPB reverse 
TACTACGAGGCGGACTGCTT 
GAGAGGAAGTCGTGGTGCTG 
GALNT2 forward 
GALNT2 reverse 
AGCTTATGTTGGAGGGACGA 
CCGACCTGGCTTCATTGT 
B2M forward and reverse Same as primer sequences for GALNT2 mRNA expression assays 
 
Table 2.2 Primer sequences for functional assays 
F indicates forward primer, R indicates reverse primer (5’-3’). 
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Trait N 
Genotypes 
(CC/CT/TT) MAF Effect P Value 
Total cholesterol in medium HDL 9810 2101/4883/2826 0.463 0.1015 5.28E-12 
Cholesterol esters in medium HDL 9810 2101/4883/2826 0.463 0.1012 6.03E-12 
Concentration of medium HDL 
particles 9810 2101/4883/2826 0.463 0.09769 2.17E-11 
Phospholipids in medium HDL 9810 2101/4883/2826 0.463 0.09535 6.43E-11 
Ratio of ApoB to ApoA1 10077 2179/5013/2885 0.465 -0.09166 2.93E-10 
Free cholesterol in medium HDL 9810 2101/4883/2826 0.463 0.09245 3.34E-10 
Phospholipids in large HDL 9810 2101/4883/2826 0.463 0.07902 1.11E-07 
Total triglycerides 10079 2179/5015/2885 0.465 -0.07402 3.20E-07 
Concentration of large HDL particles 9810 2101/4883/2826 0.463 0.07484 4.92E-07 
Mean diameter for HDL particles 9810 2101/4883/2826 0.463 0.06731 5.42E-06 
Triglycerides in small VLDL 9810 2101/4883/2826 0.463 -0.06447 1.13E-05 
Cholesterol esters in large HDL 9810 2101/4883/2826 0.463 0.06356 1.75E-05 
ApoB 10077 2179/5013/2885 0.465 -0.06265 1.88E-05 
HDL cholesterol 10077 2178/5014/2885 0.465 0.06243 2.37E-05 
ApoA1 10077 2179/5013/2885 0.465 0.06103 2.58E-05 
Concentration of small VLDL particles 9810 2101/4883/2826 0.463 -0.06168 2.95E-05 
Total cholesterol in large HDL 9810 2101/4883/2826 0.463 0.06177 2.99E-05 
Triglycerides in medium VLDL 9810 2101/4883/2826 0.463 -0.06067 3.59E-05 
Concentration of medium VLDL 
particles 9810 2101/4883/2826 0.463 -0.05927 5.88E-05 
Free cholesterol in large HDL 9810 2101/4883/2826 0.463 0.05878 7.80E-05 
Mean diameter for VLDL particles 9810 2101/4883/2826 0.463 -0.05809 8.27E-05 
Free cholesterol in small VLDL 9810 2101/4883/2826 0.463 -0.05712 9.59E-05 
Phospholipids in medium VLDL 9810 2101/4883/2826 0.463 -0.05729 0.000103 
Phospholipids in small VLDL 9810 2101/4883/2826 0.463 -0.05699 0.0001146 
Triglycerides in large VLDL 9810 2101/4883/2826 0.463 -0.05556 0.0001449 
Concentration of large VLDL particles 9810 2101/4883/2826 0.463 -0.05540 0.0001521 
Cholesterol esters in large VLDL 9810 2101/4883/2826 0.463 -0.05492 0.0001748 
Free cholesterol in medium VLDL 9810 2101/4883/2826 0.463 -0.05465 0.0002142 
Total cholesterol in medium VLDL 9810 2101/4883/2826 0.463 -0.05383 0.0002357 
Triglycerides in small HDL 9810 2101/4883/2826 0.463 -0.05384 0.0002677 
Total cholesterol in small VLDL 9810 2101/4883/2826 0.463 -0.05282 0.0003104 
Phospholipids in large VLDL 9810 2101/4883/2826 0.463 -0.05264 0.0003617 
Cholesterol esters in medium LDL 9810 2101/4883/2826 0.463 -0.05228 0.0004001 
Cholesterol esters in medium VLDL 9810 2101/4883/2826 0.463 -0.05169 0.0004156 
Total cholesterol in medium LDL 9810 2101/4883/2826 0.463 -0.05181 0.0004519 
Total cholesterol in large VLDL 9810 2101/4883/2826 0.463 -0.05049 0.0005621 
Total cholesterol in small LDL 9810 2101/4883/2826 0.463 -0.05016 0.0006098 
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Mean diameter for LDL particles 9810 2101/4883/2826 0.463 0.04941 0.0007732 
Triglycerides in very small VLDL 9810 2101/4883/2826 0.463 -0.04859 0.0009471 
Concentration of medium LDL particles 9810 2101/4883/2826 0.463 -0.04837 0.001062 
Concentration of small LDL particles 9810 2101/4883/2826 0.463 -0.04631 0.00156 
Free cholesterol in large VLDL 9810 2101/4883/2826 0.463 -0.04615 0.001693 
Concentration of very large VLDL 
particles 9810 2101/4883/2826 0.463 -0.04601 0.001755 
Phospholipids in medium LDL 9810 2101/4883/2826 0.463 -0.04332 0.003093 
Triglycerides in very large VLDL 9810 2101/4883/2826 0.463 -0.04344 0.003127 
Cholesterol esters in large LDL 9810 2101/4883/2826 0.463 -0.04144 0.005026 
LDL cholesterol 10076 2177/5014/2885 0.465 -0.03815 0.008521 
Total cholesterol in large LDL 9810 2101/4883/2826 0.463 -0.03813 0.009843 
Concentration of large LDL particles 9810 2101/4883/2826 0.463 -0.03517 0.01736 
Triglycerides in chylomicrons and 
largest VLDL 9810 2101/4883/2826 0.463 -0.03199 0.02879 
Phospholipids in very large VLDL 9810 2101/4883/2826 0.463 -0.03104 0.0334 
Free cholesterol 9985 2164/4960/2861 0.465 -0.03048 0.03626 
Phospholipids in very large HDL 9810 2101/4883/2826 0.463 0.03016 0.04097 
Triglycerides in IDL 9810 2101/4883/2826 0.463 -0.02929 0.04635 
Phospholipids in large LDL 9810 2101/4883/2826 0.463 -0.02903 0.04858 
Free cholesterol in large LDL 9810 2101/4883/2826 0.463 -0.02721 0.06557 
Concentration of very large HDL 
particles 9810 2101/4883/2826 0.463 0.02434 0.0992 
Total cholesterol 10079 2179/5015/2885 0.465 -0.02111 0.1453 
Free cholesterol in very large HDL 9810 2101/4883/2826 0.463 0.01893 0.2023 
Esterified cholesterol 9985 2164/4960/2861 0.465 -0.01687 0.2487 
Concentration of small HDL particles 9810 2101/4883/2826 0.463 0.01519 0.3002 
Total cholesterol in IDL 9810 2101/4883/2826 0.463 -0.01403 0.3423 
Concentration of very small VLDL 
particles 9810 2101/4883/2826 0.463 -0.01391 0.3466 
Concentration of IDL particles 9810 2101/4883/2826 0.463 -0.01194 0.4195 
Total cholesterol in very large HDL 9810 2101/4883/2826 0.463 0.01114 0.4489 
Concentration of chylomicrons and 
largest VLDL particles 9810 2101/4883/2826 0.463 -0.009914 0.4966 
Cholesterol esters in very large HDL 9810 2101/4883/2826 0.463 0.008723 0.5532 
Phospholipids in chylomicrons and 
largest VLDL 9810 2101/4883/2826 0.463 0.008239 0.5732 
Phospholipids in IDL 9810 2101/4883/2826 0.463 -0.008056 0.5824 
Triglycerides in very large HDL 9810 2101/4883/2826 0.463 0.003751 0.8012 
Phospholipids in very small VLDL 9810 2101/4883/2826 0.463 -0.003168 0.8303 
Free cholesterol in IDL 9810 2101/4883/2826 0.463 -0.0004156 0.9774 
Table 2.3 Evidence of association of GALNT2 SNP rs2144300 with 72 METSIM lipid and cholesterol 
traits 
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Table 2.3 Evidence of association of GALNT2 SNP rs2144300 with 72 METSIM lipid and cholesterol 
traits 
Traits were adjusted for age, age
2
, smoking status and lipid-lowering medication status and resulting 
residuals were transformed to a standard normal. N=number of samples, MAF=minor allele frequency. 
For rs2144300 (C/T), C is the minor allele, and T is the major allele. Effect corresponds to the major allele 
(T) of rs2144300.  
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Unconditioned  Conditioned                     
on rs17315646 
                   
Variant Chr1 
Position 
(hg19) 
LD (r2) EA MAF N Effect P Value Effect P Value 
rs17315646* 230295307 0.98789 G 0.464 9810 0.102 3.51E-12 - - 
rs10864726* 230296153 0.99074 T 0.463 9810 0.102 4.55E-12 -0.205 0.5216 
rs10127775* 230295789 0.9879 T 0.463 9810 0.102 4.72E-12 -0.272 0.4186 
rs4846914* 230295691 1 A 0.463 9810 0.102 5.27E-12 -0.383 0.2513 
rs2144300* 230294916 0.99003 T 0.463 9810 0.102 5.28E-12 -0.385 0.2486 
rs4846913* 230294715 0.9886 A 0.463 9810 0.102 5.39E-12 -0.427 0.2103 
rs11122453* 230303611 0.91864 A 0.445 9810 0.0973 4.18E-11 -0.0140 0.7889 
rs2281721* 230297136 0.9284 T 0.445 9810 0.0971 4.50E-11 -0.0184 0.7295 
rs10489615* 230304988 0.92146 G 0.445 9810 0.0968 5.02E-11 -0.0197 0.7071 
rs1321257* 230305312 0.92075 A 0.445 9810 0.0968 5.03E-11 -0.0198 0.7062 
rs10864728* 230304914 0.92146 G 0.445 9810 0.0968 5.06E-11 -0.0199 0.7037 
rs4846921* 230304352 0.92146 A 0.445 9810 0.0968 5.12E-11 -0.0203 0.6988 
rs11122455* 230304930 0.92005 G 0.445 9810 0.0966 5.52E-11 -0.0216 0.6781 
rs11122454* 230304051 0.92213 T 0.445 9810 0.0965 5.92E-11 -0.0245 0.6405 
rs1546954* 230303848 0.92072 G 0.445 9810 0.0964 6.00E-11 -0.0249 0.6353 
rs2281719* 230297659 0.92351 T 0.445 9810 0.0963 6.37E-11 -0.0266 0.612 
rs2281718* 230297778 0.92281 T 0.445 9810 0.0963 6.37E-11 -0.0266 0.612 
rs11122456* 230305966 0.91145 G 0.437 9810 0.0960 7.03E-11 -0.00772 0.8637 
rs10864727* 230297939 0.9221 G 0.446 9810 0.0958 8.07E-11 -0.0299 0.5613 
rs10779835* 230299949 0.91479 C 0.438 9810 0.0955 8.83E-11 -0.0126 0.7796 
rs11122450* 230301811 0.90916 G 0.438 9810 0.0953 9.93E-11 -0.0145 0.7469 
rs4631704* 230293530 0.93949 T 0.464 9810 0.0949 1.20E-10 -0.217 0.01306 
rs609526 230308906 0.69241 A 0.450 9810 -0.0943 1.97E-10 -0.0295 0.2546 
rs4846922* 230307182 0.7818 C 0.415 9810 0.0899 1.45E-09 -0.0176 0.6066 
rs590820 230309619 0.66157 G 0.470 9810 -0.0875 3.16E-09 -0.0172 0.4719 
rs4846923 230307222 0.58652 G 0.353 9810 0.0879 9.39E-09 0.0112 0.652 
rs10779836 230303150 0.33687 T 0.227 9810 0.0988 1.41E-08 0.0438 0.03919 
rs11122449 230300481 0.54112 T 0.324 9810 0.0866 3.07E-08 0.0145 0.5311 
rs10779833 230293037 0.34238 G 0.345 9810 0.0836 8.01E-08 0.0253 0.209 
rs4846917 230299222 0.38327 C 0.254 9810 0.0901 8.06E-08 0.0292 0.1715 
rs4846841 230302661 0.38327 G 0.254 9810 0.0901 8.08E-08 0.0292 0.1716 
rs4846840 230302521 0.38327 G 0.254 9810 0.0901 8.10E-08 0.0292 0.1718 
rs6672758 230303512 0.36541 T 0.260 9810 0.0890 9.56E-08 0.0276 0.197 
rs1555290 230294989 0.25101 A 0.196 9810 0.0977 1.00E-07 0.0433 0.0435 
rs4846919 230301451 0.25918 G 0.197 9810 0.0972 1.19E-07 0.0418 0.05218 
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rs966333 230305477 0.25101 C 0.195 9810 0.0974 1.21E-07 0.0420 0.05129 
rs4846916 230296492 0.2536 A 0.195 9810 0.0970 1.34E-07 0.0415 0.05416 
rs4846915 230296470 0.2536 A 0.195 9810 0.0970 1.34E-07 0.0415 0.0542 
rs2296065 230301776 0.26045 A 0.196 9810 0.0967 1.37E-07 0.0411 0.05672 
rs2103827 230298285 0.26143 A 0.196 9810 0.0967 1.37E-07 0.0411 0.05676 
rs12065546 230295245 0.2536 T 0.195 9810 0.0969 1.37E-07 0.0414 0.05498 
rs4846918 230300586 0.26143 T 0.196 9810 0.0967 1.39E-07 0.0410 0.05709 
rs627108 230310568 0.51376 T 0.416 9810 -0.0787 1.40E-07 -0.0148 0.4676 
rs910502 230294185 0.25266 T 0.195 9810 0.0968 1.42E-07 0.0413 0.05584 
rs4846920 230301574 0.26143 G 0.197 9810 0.0963 1.44E-07 0.0405 0.06021 
rs4846905 230279582 0.23473 G 0.239 9810 0.0898 1.44E-07 0.0409 0.03751 
rs2144299 230280366 0.23473 G 0.239 9810 0.0898 1.44E-07 0.0409 0.03754 
rs4846907 230284703 0.23473 C 0.239 9810 0.0898 1.45E-07 0.0409 0.03763 
rs2352723 230291868 0.23422 C 0.238 9810 0.0898 1.46E-07 0.0409 0.03757 
rs4846910 230291441 0.23473 A 0.238 9810 0.0898 1.46E-07 0.0409 0.03764 
Top SNPs (p 
< 0.001) 
associated 
with total 
cholesterol 
in medium 
HDL after 
conditional 
analysis on 
rs17315646 
         
rs188527357 230262751 <0.2 A 0.034 
 
9810 0.102 
 
0.0116 
 
0.161 
 
0.00009 
rs185682763 230262536 <0.2 A 0.035 
 
9810 0.0957 
 
0.0166 
 
0.154 
 
0.00015 
rs76230683 230161280 <0.2 T 0.001
1 
 
9810 -1.09 
 
0.000218 
 
-1.11 
 
0.00017 
rs186540557 230207407 <0.2 T 0.000
90 
 
9810 -1.29 
 
0.000262 
 
-1.32 
 
0.00018 
rs148414409 230210718 <0.2 G 0.029 
 
9810 0.0947 
 
0.0327 
 
0.151 
 
0.00075 
 
Table 2.4 Association of GALNT2 locus variants with total cholesterol in medium HDL in the 
METSIM study 
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Table 2.4 Association of GALNT2 locus variants with total cholesterol in medium HDL in the 
METSIM study 
Evidence of GALNT2 variant association with total cholesterol in medium HDL-C in 9,810 individuals from 
the METSIM study. Effect represents the change in standard-normalized residuals of total cholesterol in 
medium HDL level after adjustment for age, age
2
, smoking status and lipid-lowering medication status. 
Positive signs for effect indicate positive direction of effect. Variants were either directly genotyped (9 
variants) or imputed (91 variants) using a central-northern European reference panel (the top 50 variants 
are shown in this table). Positions on chromosome 1 (Chr1 position) are hg19 coordinates, variants 
names are from dbSNP138. Asterisks indicate variants tested in luciferase reporter assays. LD (r
2
), 
linkage disequilibrium r
2
 values with lead HDL-C-associated variant rs4846914 calculated from the 
METSIM cohort; EA, effect allele; MAF, minor allele frequency; N, number of samples. 
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Variant 
Chr1 
position 
(hg19) r
2 
 
ENCODE open 
chromatin and 
histone modifications 
in liver cell types 
Epigenome Atlas histone 
modifications in adult liver TF ChIP-seq peaks in HepG2 
rs4631704 230293530 0.96 
HepG2 H3K4me1, 
H3K4me2, H3K4me3, 
H3K9ac, H3K27ac Adult liver H3K4me1 POLR2A  
rs4846913 230294715 1 
HepG2 FAIRE; HepG2, 
hepatocytes and Huh-7 
DNase; HepG2 
H3K4me1, H3K4me2, 
H3K4me3, H3K9ac, 
H3K27ac Adult liver H3K4me1 
ARID3A, BHLHE40, CEBPB, 
CEBPD, CHD2, FOSL2, 
FOXA1, FOXA2, HDAC2, 
HNF4A, HNF4G, JUND, 
MAFF, MAFK, MAX, MAZ, 
MBD4, MXI1, MYBL2, MYC, 
NFIC, NR2F2, EP300, RAD21, 
RCOR1, REST, RXRA, SIN3A, 
SMC3, SP1, TBP, TCF4, 
TCF12, TEAD4, USF1 
rs2144300 230294916 1 
HepG2 FAIRE; HepG2, 
hepatocytes and Huh-7 
DNase; HepG2 
H3K4me1, H3K4me2, 
H3K4me3, H3K9ac, 
H3K27ac Adult liver H3K4me1 
CEBPB, FOSL2, FOXA1, 
FOXA2, HDAC2, HNF4A, 
HNF4G, JUND, MAFF, MAFK, 
MAX, MBD4, MYBL2, MYC, 
NFIC, NR2F2, EP300, RAD21, 
REST, RXRA, SIN3A, SP1, 
TCF12, TEAD4 
rs6143660 230295079 0.96 
HepG2 FAIRE; HepG2 
and Huh-7 DNase; 
HepG2 H3K4me1, 
H3K4me2, H3K4me3, 
H3K9ac, H3K27ac Adult liver H3K4me1 
FOXA1, FOXA2, HDAC2, 
HNF4G, MAX, MBD4, MYBL2, 
NFIC, NR2F2, EP300, RXRA, 
SP1, TEAD4 
rs17315646 230295307 1 
HepG2 H3K4me1, 
H3K4me2, H3K4me3, 
H3K9ac, H3K27ac Adult liver H3K4me1   
rs4846914 230295691 1 
Hepatocytes DNase; 
HepG2 H3K4me1, 
H3K4me2, H3K4me3, 
H3K9ac, H3K27ac Adult liver H3K4me1   
rs10127775 230295789 1 
Hepatocytes DNase; 
HepG2 H3K4me1, 
H3K4me2, H3K4me3, 
H3K9ac, H3K27ac Adult liver H3K4me1   
rs10864726 230296153 0.99 
HepG2 H3K4me1, 
H3K4me2, H3K4me3, 
H3K9ac, H3K27ac Adult liver H3K4me1   
rs2281721 230297136 0.96 
HepG2 H3K4me1, 
H3K4me2, H3K9ac, 
H3K27ac Adult liver H3K4me1 USF1 
rs2281719 230297659 0.96 
HepG2 H3K4me1, 
H3K4me2, H3K27ac Adult liver H3K4me1    
rs2281718 230297778 0.91 
HepG2 H3K4me1, 
H3K4me2, H3K27ac Adult liver H3K4me1   
rs10864727 230297939 0.96 
HepG2 H3K4me1, 
H3K4me2, H3K27ac Adult liver H3K4me1   
rs10779835 230299949 0.96 
HepG2 H3K4me1, 
H3K27ac 
Adult Liver H3K4me1, 
H3K9ac   
rs11122450 230301811 0.96 
HepG2 H3K4me1, 
H3K27ac Adult Liver H3K4me1   
rs11122453 230303611 0.95 HepG2 H3K4me1   RAD21, CTCF 
rs1546954 230303848 0.95 HepG2 H3K4me1     
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rs34966440 230303931 0.94 HepG2 H3K4me1     
rs11122454 230304051 0.95 HepG2 H3K4me1     
rs4846921 230304352 0.95 HepG2 H3K4me1     
rs10864728 230304914 0.94 HepG2 H3K4me1     
rs11122455 230304930 0.94 HepG2 H3K4me1     
rs10489615 230304988 0.94 HepG2 H3K4me1     
rs1321257 230305312 0.94 HepG2 H3K4me1 Adult Liver H3K9ac   
rs11122456 230305966 0.95 HepG2 H3K4me1 Adult Liver H3K9ac   
rs4846922 230307182 0.77 HepG2 H3K4me1     
 
Table 2.5 Variants in strong linkage disequilibrium (r
2 
> 0.7) with the GWAS HDL-C-associated 
variant rs4846914 overlap ENCODE open chromatin, histone ChIP-seq and transcription factor 
ChIP-seq peaks in liver cell types  
ENCODE open chromatin and histone modification peaks in liver cell types were based on ENCODE 
Open Chromatin by DNase I HS and FAIRE tracks and Broad Histone and UW Histone tracks. 
Transcription factor ChIP-seq peaks were based on Integrated Regulation from ENCODE tracks and 
ENCODE Transcription Factor Binding tracks. Linkage disequilibrium values from 1000 Genomes phase 
1 version 3 CEU, Northern Europeans from Utah, are shown in the r
2 
column. 
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Gene 
eQTL P value 
Probeset 
rs4846914 rs4846913 rs2281721 rs2144300 rs4846922 * 
GALNT2 2.2E-14 2.4E-14 2.9E-15 2.4E-14 1.4E-15 11737879_s_at 
PGBD5 0.0084 0.010 0.018 0.010 0.0069 11722329_at 
CAPN9 0.023 0.028 0.016 0.028 0.011 11737581_a_at 
FAM89A 0.071 0.084 0.046 0.084 0.095 11731560_at 
ARV1 0.12 0.099 0.13 0.099 0.75 11738018_a_at 
CCSAP 0.16 0.18 0.080 0.18 0.12 11720144_s_at 
TAF5L 0.18 0.22 0.23 0.22 0.082 11736606_a_at 
C1orf198 0.18 0.22 0.16 0.22 0.34 11741655_a_at 
TRIM67 0.20 0.25 0.104 0.25 0.067 11752381_a_at 
NUP133 0.29 0.29 0.48 0.29 0.78 11723924_a_at 
ABCB10 0.30 0.34 0.25 0.34 0.096 11724634_s_at 
URB2 0.41 0.45 0.34 0.45 0.79 11746690_a_at 
COG2 0.44 0.39 0.61 0.39 0.75 11743607_a_at 
ACTA1 0.54 0.57 0.45 0.57 0.45 11743108_a_at 
RAB4A 0.60 0.53 0.56 0.53 0.39 11721301_a_at 
TTC13 0.77 0.70 0.91 0.70 0.86 11723590_a_at 
AGT 0.85 0.91 0.92 0.90 0.39 11730726_s_at 
 
Table 2.6 SNP associations with gene expression levels in primary subcutaneous adipose tissue 
samples from 1381 individuals from the METSIM study 
Primary subcutaneous adipose eQTL p-values for genes located within 1 Mb from the lead HDL-C-
associated variant rs4846914 and functional candidate variants rs4846913, rs2144300 and rs2281721 
(all variants r
2 
> 0.7 with rs4846914). *The lead eQTL-associated variant, rs4846922, exhibited the 
strongest evidence of association with GALNT2 expression. Probesets, gene probesets from the 
Affymetrix Human Genome U219 Array. 
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SNP 
                                      conditional variant 
none rs4846913 rs2144300 rs4846914 rs2281721 rs4846922 * 
rs4846913 2.4E-14 n.a. 0.8756 0.87 0.98 0.29 
rs2144300 2.4E-14 0.88 n.a. 0.87 0.98 0.29 
rs4846914 2.2E-14 0.70 0.71 n.a. 0.79 0.35 
rs2281721 2.9E-15 0.042 0.044 0.047 n.a. 0.21 
rs4846922 * 1.4E-15 0.0074 0.0077 0.011 0.062 n.a. 
 
Table 2.7 Initial and residual associations with GALNT2 expression in primary subcutaneous 
adipose tissue samples from 1381 individuals from the METSIM study 
P-values of the lead HDL-C-associated variant rs4846914 and other functional candidate variants, 
rs4846913, rs2144300, and rs2281721 (all variants r
2 
> 0.7 with rs4846914) after conditioning on each 
respective variant (conditional variant). The asterisk indicates the lead eQTL variant, rs4846922. 
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ENDNOTES 
1
Chapter 2 is featured as an article, “Multiple hepatic regulatory variants at the GALNT2 GWAS locus 
associated with high-density lipoprotein cholesterol” in The American Journal of Human Genetics, Volume 
97 Issue 6, Pages 801-815.   
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CHAPTER 3: A FUNCTIONAL REGULATORY VARIANT ASSOCIATED WITH TYPE 2 DIABETES, 
FASTING GLUCOSE AND DECREASED ADCY5 EXPRESSION 
 
3.1 Introduction 
Genome-wide association studies (GWAS) have identified more than 80 loci associated with type 
2 diabetes[66]; however the underlying biological and molecular mechanisms responsible for many of 
these associations are still unknown. One association signal for type 2 diabetes is located within introns 
1-3 of the ADCY5 gene. The A allele of rs11708067 has been associated with risk of type 2 diabetes in a 
European population GWAS meta-analysis (n = 34,840 T2D cases, 114,981 controls, p = 7.2 x 10
-14
)[141], 
in a candidate variant study in a South Asian population (n = 1,678 T2D cases, 1,584 controls, p = 9.1 x 
10
-4
)[142] and in a candidate gene study in an African American population (n = 2,806 T2D cases, 4,265 
controls, p = 4.7 x 10
-3
)[143]. The T allele of rs11717195, (LD r
2 
= 0.91 with rs11708067, 1000 Genomes 
Phase 1 EUR[144], was also associated with risk of type 2 diabetes in a trans-ethnic GWAS meta-
analysis (n = 26,488 T2D cases, 83,964 controls, p = 2.2 x 10
-8
)[67]  and in a European population GWAS 
meta-analysis (n = 34,840 T2D cases, 114,981 controls, p = 6.5 x 10
-14
)[141]. In an African population, 
rs143882978 (LD r
2
 = 0.96 with rs11708067, 1000 Genomes YRI) was also found to be associated with 
T2D (n = 1,035 T2D cases, 740 controls, p = 0.02)[145]. 
Variants at the ADCY5 locus are also associated with other glycemic traits. The A allele of 
rs11708067 was shown to be associated with increased fasting glucose levels (n = 118,475, p = 7.1 x 10
-
22
) and decreased HOMA-B (n = 94,212, p = 2.5 x 10
-12
) in Europeans[146]. An additional variant, 
rs2877716, in strong linkage disequilibrium (LD r
2 
= 0.80, 1000 Genomes Phase 1, EUR [144]) with 
rs11708067, was found to be associated with 2-hour glucose level (n = 44,225, p = 4.2 x 10
-16
)[147]. 
Associations with fasting glucose, 2-hour glucose, insulinogenic index, and 2-hour insulin have also been 
reported in Asian Indians (rs9883204, n=2,151, p ≤ 0.05)[148]. A summary of published ADCY5 variant 
associations with T2D and glucose-related traits is shown in Table 3.1. ADCY5 variant alleles associated
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with increased glucose have also been reported to be associated with decreased birthweight (rs9883204, 
LD r
2 
= 0.79, 1000 Genomes Phase 1 EUR, n = 61,509 p = 5.5 x 10
-20
)[149].  
ADCY5 encodes adenylate cyclase 5, which catalyzes generation of cyclic AMP from ATP[150]. 
Cyclic AMP, ATP and calcium play crucial roles in insulin secretion in the pancreatic beta cell[151]. 
Previous studies have established ADCY5 as a compelling biological candidate influencing glucose 
metabolism, showing association of the T2D risk alleles with decreased ADCY5 mRNA expression[152, 
153]. Furthermore, ADCY5 knockdown in human islets reduced glucose-stimulated cAMP levels, 
inhibiting glucose metabolism toward ATP[152]. 
In this study, we aimed to identify the variant(s) responsible for the T2D and glycemic trait 
associations at this locus. Based on 1000 Genomes phase 1 version 3 EUR data[94], 13 variants exhibit 
strong linkage disequilibrium (r
2 
> 0.8) with rs11708067, and all 14 candidates including rs11708067 are 
located within ADCY5 introns 1-3. We hypothesized that one or more of these variants may regulate gene 
expression. To identify the most plausible functional regulatory variants, we used multiple regulatory 
datasets in human islets, including open chromatin, chromatin states, and H3K27ac histone modification 
ChIP-seq data[72, 79, 80, 154]. Of the 14 candidate variants, only one variant, rs11708067, overlaps both 
DNase and FAIRE peaks and a predicted strong enhancer chromatin state in primary human islets. We 
demonstrate that rs11708067 exhibits allelic differences in reporter assays of transcriptional activity 
consistent with the association between the T2D risk alleles and decreased expression of ADCY5, and 
show evidence of differential transcription factor binding to the rs11708067-A T2D risk allele. 
 
3.2 Materials and Methods 
3.2.1 Lookup of expression quantitative trait loci in primary human islets 
We looked for evidence of association between the T2D and fasting glucose GWAS variant 
region and gene expression using primary human islet RNA-seq eQTL data from the Finland-United 
States Investigation of Non-Insulin-Dependent Diabetes Mellitus (FUSION) study and from a set of 
previously published islet data[155]. RNA-seq data from 82 individuals were aligned using STAR (version 
2.3.1y)[156]. Analysis of cis-eQTL data for SNPs within 1 Mb of the closest upstream TSS of each gene 
was performed using Matrix eQTL[157]. Gene expression values were calculated based on inverse 
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normalized fragments per kilobase of transcript per million mapped reads (FPKM), factor analysis via 
probabilistic estimation of expression residuals (PEER)[158] on the inverse normalized FPKM and inverse 
normalization of the resulting residuals. A linear regression model considering an additive genetic effect 
was used. 
 
3.2.2 H3K27ac ChIP-seq in a primary human islet sample 
Human pancreatic islets were obtained through the Islet Cell Resource (ICR) Basic Science Islet 
Distribution Program and National Disease Research Interchange in accordance with regulations of 
Human Subjects research. H3K27ac ChIP-seq experiments and read mapping were performed as 
described[80, 154]. For H3K27 ChIP experiments, rabbit anti-H3K27ac antibodies from Abcam were used 
(ab4729)[154]. We aligned sequence reads to the UCSC Genome Browser build hg19 considering 
variants from the 1000 Genomes Project using GSNAP[114] with AA-ALIGNER[113]. We determined 
significance of allelic imbalance at rs11708067 by using an exact binomial test, based on the number of 
reads containing the reference allele and the total number of reads at the heterozygous site. 
 
3.2.3 Cell culture 
MIN6 mouse insulinoma beta cells[159] were grown in Dulbecco’s modified Eagle’s Medium 
(Sigma-Aldrich) with 10% fetal bovine serum, 1 mM sodium pyruvate, and 100 µM beta-mercaptoethanol. 
INS-1-derived 832/13 rat insulinoma beta cells (a gift from C. Newgard, Duke University) were grown in 
RPMI-1640 medium (Corning) supplemented with 10% fetal bovine serum, 10 mM HEPES, 2 mM L-
glutamine, 1 mM sodium pyruvate, and .05 mM beta-mercaptoethanol. Cell lines were maintained at 37° 
C and 5% CO2. MIN6 or 832/13 cells (200,000 cells per well) were seeded in a 24-well tissue culture 
treated plate one day before transfections.  
 
3.2.4 Transcriptional reporter assays 
To test candidate variants for allelic differences in regulatory activity, 231-base pair segments 
were amplified from DNA of individuals homozygous for each allele by PCR. Primers are listed in Table 
3.2. Amplicons were digested using XhoI and KpnI restriction enzymes (New England BioLabs) and 
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cloned into the multiple cloning region of firefly luciferase reporter vector pGL4.23 in both orientations with 
respect to the minimal promoter (Promega). Three to five independent plasmids for each allele of 
rs11708067 were purified and confirmed by Sanger sequencing. Plasmids containing each allele were 
transfected into MIN6 mouse or 832/13 rat insulinoma cells in duplicate. For transfection of MIN6 cells, 
250 ng of plasmid DNA was added to each well with Lipofectamine LTX (ThermoFisher Scientific) and 
Opti-MEM® (Gibco®). For transfection of 832/13 cells, 770 ng of plasmid was added to each well using 
Lipofectamine 2000 (ThermoFisher Scientific) and Opti-MEM® (Gibco®). To control for transfection 
efficiency, a phRL-TK Renilla luciferase reporter vector was also transfected into MIN6 and 832/13 cells 
(80 ng each well). Cells were incubated at 37° C with 5% CO2 for 48 hours, and luciferase assays were 
performed with 832/13 cell lysates using the Dual-Luciferase® Reporter Assay System (Promega). Firefly 
luciferase readings were normalized to Renilla luciferase readings and compared to pGL4.23 minimal 
promoter empty vector control activity using two-tailed t-tests.  
 
3.2.5 Electrophoretic mobility shift assays  
Complementary oligonucleotide probes (21 base-pairs) centered on rs11708067 variant alleles 
(Table 3.2) were synthesized by Integrated DNA Technologies, Inc. Probes were labeled with biotin on 
the 5’ end. To create double stranded DNA probes, single-stranded oligonucleotides were incubated in 10 
mM Tris, 50 mM NaCl, 1 mM EDTA, pH 8.0 at 95C for 5 minutes followed by 70 one-minute cycles with 
temperature decreasing by 1. Nuclear lysates from 832/13 rat insulinoma beta cells were prepared using 
Pierce NE-PER® Nuclear and Cytoplasmic Extraction Reagents according to manufacturer’s instructions. 
EMSA reactions were performed using the LightShift® Chemiluminescent Kit (Thermo Fisher Scientific). 
Briefly, binding buffer and Poly(dI
.
dC) were added to 4 μg of 832/13 nuclear lysate and incubated at room 
temperature for ten minutes. Biotin-labeled DNA probes were added and the reaction was incubated for 
30 minutes. For unlabeled competition reactions 125-fold excess unlabeled double-stranded probe was 
added to binding buffer, poly(dI
.
dC) and 832/13 nuclear lysate and incubated for 10 minutes before 
addition of biotin-labeled DNA. Reactions were loaded into a 6% DNA retardation gel (Life Technologies), 
subjected to electrophoresis for 2 hours at 100V, transferred to Biodyne B Nylon Membranes (Thermo 
Fisher Scientific) and crosslinked by UV. Subsequent wash and detection steps were performed 
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according to Chemiluminescent Nucleic Acid Detection Module (Thermo Fisher Scientific) instructions. 
For EMSA supershift assays, 6-8 μg of CEBPA (sc-61X), CEBPB (sc-150X) or NKX2.2 (sc-25404X) 
antibodies (all from Santa Cruz Biotechnology, Inc.) were added to 832/13 nuclear lysate, binding buffer, 
and poly(dI·dC) for 20 minutes before addition of labeled DNA probes.  
 
3.3 Results  
3.3.1 rs11708067 is associated with ADCY5 expression in primary human pancreatic islets 
We examined evidence of association between rs11708067 and expression of nearby genes in a 
preliminary analysis of islet eQTL data from 112 human pancreatic islet samples, including eQTL data 
previously reported from 81 islet donors of European ancestry[155]. The T2D risk rs11708067-A allele 
showed the strongest association with decreased ADCY5 expression (p = 4.2 x 10
-9
, Figure 3.1), 
consistent with previous reports[152, 153]. 
 
3.3.2 rs11708067 overlaps evidence of open chromatin and a predicted strong enhancer region 
in human pancreatic islets 
We aimed to determine whether the GWAS lead variants or variants in strong linkage 
disequilibrium showed evidence of regulatory activity. Open chromatin data, including DNase I 
hypersensitivity-sequencing (DNase-seq) data and formaldehyde-assisted isolation of regulatory 
elements (FAIRE)-sequencing data, often mark regulatory elements[74, 75]. We used DNase and FAIRE 
data in primary human pancreatic islets to investigate potential regulatory regions overlapping the 
association signal at the ADCY5 locus[79, 80]. We asked if any of the variants in strong linkage 
disequilibrium (r
2 
> 0.8, 1000 Genomes phase 1 EUR) with any of the lead T2D or glycemic trait lead 
GWAS variants overlapped regions of open chromatin. Among 14 candidate variants, rs11708067 
overlaps a predicted strong enhancer region in human pancreatic islets[154], a transposase-accessible 
peak from an Assay for Transposase-Accessible Chromatin with high throughput sequencing (ATAC-seq) 
in pancreatic islet alpha cells[160] and is the only variant to overlap both a DNase and FAIRE peak in 
human pancreatic islets (Figure 3.2).  
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3.3.3 Allelic imbalance of H3K27ac reads overlapping rs11708067 in human pancreatic islets 
In addition to open chromatin data, histone modifications, such as H3K4me1, H3K4me2, and 
H3K27ac, also often mark regulatory enhancer regions. Using H3K27ac ChIP-seq data[154] in a primary 
human islet sample, we investigated the region spanning rs11708067. H3K27ac ChIP-seq reads 
containing rs11708067 showed evidence of allelic imbalance, with 69 reads containing the rs11708067-G 
allele compared to 9 reads containing rs11708067-A reference allele (Figure 3.3, binomial p = 1.2 x 10
-4
). 
These data are consistent with the eQTL data; rs11708067-G allele shows higher expression and greater 
H3K27ac enrichment. 
 
3.3.4 rs11708067 shows allelic differences in enhancer activity 
To investigate whether rs11708067 shows allelic differences in transcriptional activity, we tested 
a 231-bp DNA segment containing rs11708067 for allelic differences in enhancer activity in luciferase 
reporter assays in MIN6 mouse insulinoma and 832/13 rat insulinoma cell lines. In MIN6 cells, we 
observed 2.6- to 8.3-fold enhancer activity compared to an empty vector control in the forward orientation, 
with significant differences between the alleles (Figure 3.4A, p = 1.9 x 10
-3
). In the reverse orientation, the 
segment exhibited 2.3- to 13.9-fold enhancer activity compared to empty vector with significant 
differences between the alleles (Figure 3.4A, p = 4.9 x 10
-5
). In 832/13 cells, we observed 1.6- to 3.3-fold 
enhancer activity compared to an empty vector control in the forward orientation, with significant 
differences between the alleles (Figure 3.4B, p = 1.0 x 10
-3
). In the reverse orientation, we observed 0.84- 
to 1.3-fold luciferase activity, with significant differences between the alleles (Figure 3.4B, p = 3.0 x 10
-3
). 
In both cell types and both the forward and reverse orientations, the rs11708067-A allele showed lower 
luciferase activity, suggesting that the rs11708067-G allele may be located within an enhancer element 
that increases transcriptional activity of ADCY5 or another nearby gene. 
 
3.3.5 The alleles of rs11708067 exhibit differential protein binding 
To determine whether there was differential transcription factor binding at rs11708067, we 
performed EMSAs with 21-bp biotinylated probes containing either the rs11708067-A or rs11708067-G 
alleles. We observed three bands specific to the rs11708067-A allele compared to the rs11708067-G 
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allele (Figure 3.5, lane 2 vs. lane 6). Addition of 125-fold unlabeled probe containing the A allele of 
rs11708067 competed away the A-allele-specific bands more effectively than unlabeled probe containing 
the G allele (Figure 3.5, lanes 3 and 4). Using bioinformatic prediction tools (JASPAR[111], TRANSFAC, 
Regulome Browser[161]) to search for transcription factor motif matches to the sequence spanning 
rs11708067, we found that DNA region spanning rs11708067 overlaps a NKX2.2 transcription factor 
ChIP-seq peak[161]. However, incubation of the EMSA reaction with an antibody to NKX2.2 did not result 
in a supershift (data not shown). Additional antibodies tested in EMSAs, including CEBPA and CEBPB, 
also did not demonstrate evidence of supershifts. Additional experiments will be necessary to identify the 
transcription factor(s) binding to rs11708067 and to determine whether the transcription factors influence 
allelic differences in transcriptional activity and modulate ADCY5 expression levels. 
 
3.4 Discussion 
In this study, we show evidence of a functional regulatory variant at the ADCY5 association signal 
for fasting glucose levels, 2-hour glucose levels and type 2 diabetes[141, 146, 147]. The proposed 
regulatory variant, rs11708067, overlaps multiple regulatory datasets, including DNase and FAIRE peaks 
in human pancreatic islets[79, 80], a transposase-accessible ATAC-seq peak in pancreatic islet alpha 
cells[160]  and a predicted strong enhancer region in human pancreatic islets[154]. Additionally, the 
rs11708067-G allele exhibited increased enrichment of H3K27ac regulatory marks compared to the 
rs11708067-A allele, which is consistent with the observation that the G allele showed higher enhancer 
activity in transcriptional reporter assays. The rs11708067-A allele showed lower transcriptional activity 
and allele-specific binding of nuclear proteins, suggesting that the A allele binds a transcriptional 
repressor protein. The rs11708067-A allele also showed lower expression of ADCY5 in our lookup of 
eQTL data in human pancreatic islets and in previously published data from human pancreatic islets[152, 
153]. 
Determining the functional regulatory variants at GWAS loci and the genes they may regulate can 
help elucidate the mechanisms by which variants increase or decrease gene expression. Previously, the 
A allele of rs11708067 was shown to be associated with lower ADCY5 expression in 7 and 118 human 
islet samples[152, 153]. We confirmed that the rs11708067-A T2D risk and fasting glucose-raising allele 
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showed lower ADCY5 expression in 112 human islets (81 published[155] samples and 31 new islet 
samples). These data suggest that ADCY5 is a likely target gene, and that lower ADCY5 expression may 
increase fasting glucose and lead to increased risk of T2D. 
ADCY5 encodes an enzyme that influences the generation of cyclic AMP (cAMP), a crucial 
signaling molecule in the pancreatic beta cell[152]. cAMP plays roles in Ca
2+
 signaling and influx[162], as 
well as in insulin granule exocytosis[163]. In ADCY5 knockdown studies in primary human pancreatic 
islets, ADCY5 was shown to be required to couple glucose signals to intracellular Ca
2+
 increases to drive 
insulin granule exocytosis, supporting a role for ADCY5 in glucose and insulin metabolism[152].  
ADCY5 is expressed in a number of different tissues, including adipose tissue, pancreatic islets, 
and pituitary, with highest levels of expression in the heart, tibial artery, brain and esophagus[73, 154]. 
RNA-seq data from many other cell types, including human umbilical vein endothelial cells and human 
skeletal muscle myoblasts, show low or no expression of ADCY5[154]. We did not observe evidence of 
eQTLs for the GWAS variant rs11708067 and ADCY5 expression  in peripheral blood cells[164]. ADCY5 
may play a functional role in islets based on ADCY5 biology studies[152], although ADCY5 expression in 
other cell types might also contribute to biological mechanisms of T2D, as alterations in TCF7L2 T2D-
associated gene expression were shown to alter glucose and insulin metabolism in both liver and 
pancreatic beta cells[165-169]. The T2D-associated lead GWAS variant, rs11708067, was associated 
with impaired proinsulin-to-insulin conversion, as individuals homozygous for the T2D-risk A allele 
showed higher proinsulin levels and a higher proinsulin/insulin ratio after an oral glucose tolerance test (p 
= 2.0 x 10
-3
)[170]. Considering that proinsulin is synthesized in the endoplasmic reticulum of pancreatic 
islet beta cells[171], these data provide additional evidence that ADCY5 influences glucose and insulin 
metabolism in islets and may be a likely target gene underlying the association with multiple glucose-
related traits. 
Our study has some limitations. We did not examine other candidate variants that were in strong 
linkage disequilibrium (r
2
 > 0.8) with rs11708067 for regulatory activity in luciferase reporter assays. 
rs11708067 was the strongest candidate for predicted regulatory function, however, 2 additional variants 
overlap predicted  enhancer states in islets[154]. Considering that GWAS loci may have multiple 
functional regulatory variants responsible for the association[85], future studies should include testing at 
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least these 2 variants (if not the entire set of candidate variants) for evidence of regulatory activity. The 
identities of the nuclear protein(s) binding to rs11708067 are still unknown; it will be necessary to identify 
these proteins to determine if they alter the regulatory activity of rs11708067. These putative proteins 
could then be tested for binding in ChIP assays in a more in vivo context in primary human islets. Future 
studies could also include allelic expression imbalance analyses in human islets heterozygous for 
rs11708067, or genomic editing of rs11708067 in embryonic stem cells or human pancreatic beta cell 
lines and measuring the effects on ADCY5 gene expression. These experiments would ultimately 
contribute to further characterization of the molecular mechanism(s) responsible for the T2D and glucose-
related associations at the ADCY5 locus. Despite these limitations, we provide multiple lines of evidence 
for rs11708067 as a functional regulatory variant at the ADCY5 locus. This is in line with rs11708067 
showing the highest posterior probability of driving the association signal from a  credible set analysis that 
included enrichment estimates using chromatin annotations from 12 cell types ([172] and Kyle Gaulton, 
personal communication). In our studies, we also found consistent evidence that the rs11708067-A allele 
is associated with decreased ADCY5 expression, highlighting the relationship between the GWAS variant 
and gene expression.  
Taken together, our data identify a functional variant at the ADCY5 locus, rs11708067, and 
provide evidence of a mechanism by which this variant affects expression of ADCY5, leading to altered 
fasting glucose levels and risk of T2D (Figure 3.6). The T2D-risk allele rs11708067-A appears to bind one 
or more repressor proteins that reduce enhancer activity and reduce ADCY5 expression. The lower 
transcriptional activity of ADCY5 may reduce the generation of cAMP and lead to decreases in Ca
2+ 
influx 
and glucose-stimulated insulin secretion, which could result in increased plasma glucose levels and T2D. 
Additional experiments will be necessary to fully elucidate the molecular and biological mechanism(s) at 
this locus.  
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Figure 3.1 The A allele of rs11708067 is associated with decreased ADCY5 expression in 112 
human primary pancreatic islet samples 
eQTL data are based on RNA-sequencing of 81 published[155] and 31 new islet samples. The diamond 
represents the lead variant, rs11708067, of the eQTL analysis. Circles represent genotyped and imputed 
DNA variants and LD (r
2
) is colored based on 1000 Genomes Phase 3 EUR. Chromosome coordinates 
correspond to the UCSC Genome Browser build hg19. The left Y-axis indicates the –log10(p-value), the 
right Y-axis indicates the recombination rate (cM/Mb) and the X-axis indicates the position on 
chromosome 3 (Mb).  
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Figure 3.2 rs11708067 overlaps pancreatic islet open chromatin and a strong enhancer chromatin 
state in ADCY5 intron 3 
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Figure 3.2 rs11708067 overlaps pancreatic islet open chromatin and a strong enhancer chromatin 
state in ADCY5 intron 3 
The 42-kb region of association shown includes all 13 variants in strong linkage disequilibrium (r
2 
> 0.8) 
with the T2D-associated variant rs11708067 (14 total noncoding candidate variants located within ADCY5 
introns 1-3). Selected ENCODE open chromatin (DNase, FAIRE), and RNA-seq and chromatin state 
tracks  are shown. The black vertical line above the pancreatic islet open chromatin tracks represents the 
231-bp segment containing rs11708067 that was tested in luciferase reporter assays. rs11708067 is 
located 102 kb from the ADCY5 transcription start site (TSS) (longer isoform) and 69 kb from the shorter 
isoform ADCY5 TSS. PanIslets, pancreatic islets; GM12878, B-lymphocyte, lymphoblastoid cells; H1 ES, 
embryonic stem cells; HepG2, human hepatocellular carcinoma cells; HMEC, human mammary epithelial 
cells; HSMM, human skeletal muscle myoblasts; HUVEC, human umbilical vein endothelial cells; K562, 
leukemia cell line; NHEK, epidermal keratinocytes; NHLF, lung fibroblasts. 
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Figure 3.3 Evidence of allelic imbalance in H3K27ac ChIP-seq reads at rs11708067 
H3K27ac ChIP-seq reads spanning rs11708067 (hg19 chromosome coordinates) in a primary human 
islet sample heterozygous at rs11708067. Reads are colored according to the allele present at 
rs11708067. Blue indicates reads that contain the G allele, red indicates reads that contain the A allele 
and gray indicates reads in the peak that do not overlap rs11708067. 
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Figure 3.4 rs11708067 exhibits allelic differences in transcriptional activity in MIN6 mouse 
insulinoma and 832/13 rat insulinoma cells 
231-bp segments containing allele A or G of rs11708067 were cloned into a pGL4.23 luciferase reporter 
vector upstream of the minimal promoter in both forward and reverse orientations. 
A Relative luciferase activity of plasmids transfected into MIN6 cells. Luciferase activity is shown 
normalized to an empty vector control. Error bars represent pairwise standard deviation of 3-5 
independent clones per allele (t-tests). * indicates p < 0.05, ** indicates p < 0.01, *** indicates p ≤ 0.001. 
B Relative luciferase activity of plasmids transfected into 832/13 cells. 
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Figure 3.5 The alleles of rs11708067 show allelic differences in nuclear protein binding 
Electrophoretic mobility shift assays with biotin-labeled probes containing either the A or G allele of 
rs11708067. Probes were incubated with 832/13 rat insulinoma nuclear lysate. The arrows indicate 
differential protein binding to the A allele, which is competed away by 125-fold excess competitor DNA 
containing the A allele (lane 3). EMSAs were repeated 8 independent times with consistent results. 
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Figure 3.6 rs11708067 may alter transcription factor binding at ADCY5 
Arrows indicate the transcription start site (TSS) of the ADCY5 gene. Circles/ovals represent proteins that 
appear to be bound specifically and differentially to the A allele of rs11708067. rs11708067 showed allelic 
differences in transcriptional enhancer activity, differential protein binding in EMSAs, and evidence of 
allelic imbalance in H3K27ac ChIP-seq reads. The rs11708067-G allele, which showed greater enhancer 
reporter activity and greater H3K27ac enrichment, is the allele that showed higher ADCY5 expression in 
human pancreatic islets. The G allele is also associated with decreased risk of T2D. 
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Lead SNP 
T2D 
risk, 
glucose 
raising 
allele 
Alt. 
allele 
Effect 
size or 
Odds 
Ratio 
N P value Trait Study Pop 
rs11717195 T C 
1.09-
1.18 
26,488 
T2D 
cases 
and 
83,964 
controls 
2.2E-08 T2D 
GWAS, 
DIAGRAM 
2014 
Trans-
ethnic 
meta-
analysis 
rs11717195 T C 1.11 
34,840 
T2D 
cases, 
114,981 
controls 
6.5E-14 T2D 
GWAS, 
Morris 2012 
European 
rs2877716 C T 
+0.09 
mmol/l 
44,225 4.2E-16 
2-hr 
glucose 
GWAS, 
Saxena 2010 
European 
rs2877716 C T 1.12 
35,869 
T2D 
cases, 
89,798 
controls 
4.8E-18 T2D 
GWAS, 
Saxena 2010 
European 
rs11708067 A G 
+0.03 
mmol/l 
118,475 7.1E-22 
fasting 
glucose 
GWAS, 
Dupuis 2010 
European 
rs11708067 A G -0.02 94,212 2.5E-12 
HOMA-
B 
GWAS, 
Dupuis 2010 
European 
rs11708067 A G 1.18 
2,806 
T2D 
cases, 
4,265 
controls 
4.7E-03 T2D 
Candidate 
gene, 
Ng 2013 
African 
American 
rs11708067 A G 1.23 
1678 
T2D 
cases, 
1584 
controls 
9.1E-04 T2D 
Candidate 
variant, Rees 
2011 
South 
Asian 
rs143882978 C  T  -0.462 
1035 
cases, 
740 
controls 
0.02 T2D 
Candidate 
gene, 
Adeyemo 
2015 
African 
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Table 3.1 Summary of published ADCY5 SNP associations with T2D and glucose-related traits 
Alt. allele, alternate allele (T2D non-risk allele, or glucose decreasing allele); Pop, population;  I-I, 
insulinogenic index. LD (r
2
, 1000 Genomes Phase 1 EUR) between rs11717195 and rs11708067: 0.91; 
LD between rs2877716 and rs11708067: 0.8; LD between rs9883204 and rs11708067: 0.79. LD (r
2
, 1000 
Genomes YRI) between rs143882978 and rs11708067: 0.96. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
rs9883204 C T 
0.041, 
0.127, 
-0.106, 
-0.058 
2,151 
0.03, 
0.02, 
0.05, 
0.01 
Fasting 
glucose
; 2-hr 
glucose
; 
reduced 
I-I; 2-hr 
insulin 
Candidate 
variant, 
Vasan 2011 
Asian 
Indians 
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Primer sequences used to amplify DNA for 
luciferase reporter assays 
 
rs11708067_Forward 
Chromosome 3 position (hg19) 
CCTGGGGAGAAGGAACTCTC 
123065631 
rs11708067_Reverse 
Chromosome 3 position (hg19) 
GCTCCTTTCACTGCGTGTTT 
123065861 
Oligonucleotide sequences for EMSAs  
rs11708067_A_Forward CAGATTTTGCACTCTATTAAT 
rs11708067_A_Reverse ATTAATAGAGTGCAAAATCTG 
rs11708067_G_Forward CAGATTTTGCGCTCTATTAAT 
rs11708067_G_Reverse ATTAATAGAGCGCAAAATCTG 
 
Table 3.2 Primer sequences for luciferase reporter and electrophoretic mobility shift assays 
Forward indicates forward primer, reverse indicates reverse primer (5’-3’). 
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CHAPTER 4: REGULATORY ELEMENTS IN ENDOTHELIAL CELLS AT THE PLXND1 GWAS LOCUS 
ASSOCIATED WITH WHR 
 
4.1 Introduction 
Increased waist-hip ratio (WHR) is associated with risk of metabolic diseases, including type 2 
diabetes[173] and coronary heart disease[174]. Increased WHR is often characterized by increased 
adiposity in the central part of the body[175]. Insulin resistance, increased triglycerides, decreased HDL 
cholesterol level and central obesity tend to cluster together in individuals and contribute to metabolic 
disease risk[46, 47]. To date, GWAS have identified 49 loci that are associated with human WHR, a 
measure of body fat distribution[64, 65]. Of these loci, at least 5 contain genes that have roles in 
angiogenesis and/or vascular biology. Angiogenesis is required for adipogenesis and adipose tissue 
expansion[176, 177]; therefore, studying these genes may provide further insight into the biology of body 
fat distribution in humans. 
The WHR association signals include one represented by lead GWAS variant rs10804591 on 
chromosome 3 (p = 6.6 x 10
-9
, n = 209,921 total individuals)[65]. Like many WHR association loci, this 
signal showed a stronger association in women (p =6.1 x 10
-13
, n =116,667 women)[65]. The alleles 
associated with increased WHR are also associated with decreased hip circumference (p = 7.4 x 10
-18
, 
n=210,953 total individuals; p = 5.5 x 10
-15
, n = 117,265 women)[65].  
The WHR-associated lead GWAS variant rs10804591 is located 8.6 kb upstream of the promoter 
of PLXND1. PLXND1 (MIM: 604282) encodes Plexin D1 protein, which acts as a receptor for the 
semaphorins 3E and 4A[178-183]. Semaphorins are secreted and membrane-bound proteins that play a 
role in the function and formation of the cardiovascular, endocrine, gastrointestinal, hepatic, immune, 
musculoskeletal, renal, reproductive,and respiratory systems[184]. Semaphorin-Plexin D1 signaling was 
also found to be important for synaptic signaling and development of the nervous system[185] as well as
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regulation of angiogenesis[186]. In zebrafish, loss of plxnd1 function by morpholino injection or in mutants 
resulted in blood vessel patterning defects[179].  
In addition to roles in angiogenesis, Plexin D1 has also been shown to influence adipocyte 
morphology and fat storage. Homozygous null plxnd1 mutant zebrafish exhibit decreased lipid storage 
and a hyperplastic morphology specifically in visceral adipose tissue (VAT)[187]. After being fed a high-fat 
diet, VAT in plxnd1 mutants did not expand, nor did these zebrafish display hyperglycemia, leading to the 
conclusion that loss of plxnd1 offers protection from high-fat diet-induced insulin resistance[187]. In 
humans, PLXND1 mRNA levels in VAT were positively associated with a hypertrophic morphology (p = 
0.03, n = 79 individuals) and PLXND1 mRNA was increased in VAT of obese patients with type 2 
diabetes (p = 0.03, n = 30 individuals)[187]. Plexin D1’s established role in vascular development and 
patterning and adipose tissue morphology suggests PLXND1 may have biological relevance and may be 
a novel gene influencing WHR.   
According to 1000 Genomes phase 1 European (EUR) data[144], 35 variants exhibit strong 
linkage disequilibrium (LD, r
2 
> 0.8) with rs10804591. All 36 variants are noncoding and overlap at least 
one mark indicative of regulatory regions, including open chromatin, histone modification ChIP-seq and/or 
transcription factor binding ChIP-seq peaks from the ENCODE Project[72] or Human Epigenome 
Atlas[73]. We therefore hypothesized that one or more of these variants may be located in enhancer 
regions and act to regulate gene expression. Based on evidence of plxnd1’s role in visceral adipose 
endothelial cells in zebrafish[187], we sought to identify the functional variants and molecular 
mechanisms underlying the PLXND1 WHR association by identifying regulatory enhancer elements in 
both a human umbilical vein endothelial cell line (HUVEC) and zebrafish.  
 
4.2 Materials and Methods 
4.2.1 Luciferase reporter vectors containing PLXND1 candidate cis-regulatory elements  
Candidate cis-regulatory elements (CREs) to test in reporter assays (Figure 4.1 and Table 4.1) 
were designed based on overlap with variants in strong LD (r
2 
> 0.8, 1000 Genomes phase 1 EUR) with 
the lead WHR-associated GWAS variant rs10804591[144] as well as open chromatin DNase and FAIRE 
peaks and histone modification H3K4me1, H3K9ac and H3K27ac ChIP-seq peaks from ENCODE 
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data[72]. Elements were amplified using Phusion® High-Fidelity DNA polymerase (New England 
BioLabs). Primer sequences for amplification of each CRE are in Table 4.2. Site-specific recombination 
sequences (attB sites) were added to the forward and reverse primers to facilitate recombination of the 
elements into vectors using the Gateway® recombination cloning technology (Thermo Fisher Scientific). 
PCR amplicon bands were isolated from agarose gels and purified using the Wizard® SV Gel and PCR 
Clean-Up System (Promega). The CRE elements were then cloned into a Gateway pDONR™221 entry 
clone using BP Clonase™ (Thermo Fisher Scientific) and transformed into Library Efficiency® DH5α™ 
Chemically Competent E. coli strains (Thermo Fisher Scientific) according to manufacturer’s instructions. 
Plasmids were purified using QIAprep Spin Miniprep Kit (QIAGEN) and the elements and recombination 
junctions were verified by sequencing. Candidate CRE elements in pDONR™221 vectors were then 
recombined into the destination gateway-compatible pGL4.23 luciferase vectors by LR recombination 
using LR Clonase™ according to manufacturer’s instructions (Thermo Fisher Scientific) and incubated 
overnight. The recombination reactions were transformed into Library Efficiency® DH5α™ Chemically 
Competent E. coli strains, purified using PureLink® HiPure Plasmid Miniprep Kit (Thermo Fisher 
Scientific) and vectors were verified by sequencing. To create the alternate alleles of candidate variants, 
site-directed mutagenesis was performed using the Q5® Site-Directed Mutagenesis Kit (New England 
BioLabs) and alleles were confirmed by sequencing. 
 
4.2.2  Generation of a gateway-compatible pGL4.23 luciferase reporter vector 
For recombination of CRE elements into pGL4.23 luciferase vector (Promega), a gateway-
compatible pGL4.23 luciferase vector was created. Briefly, the Gateway® Vector Conversion System 
(Thermo Fisher Scientific) was used to recombine a reading frame cassette into the pGL4.23 luciferase 
vector. The pGL4.23 luciferase vector was first linearized using EcoRV (New England BioLabs), 5’ 
phosphates were removed with calf intestinal alkaline phosphatase and reading frame cassette B 
(Thermo Fisher Scientific) was ligated into the pGL4.23 luciferase vector according to manufacturer’s 
instructions. The ligation reaction was then transformed into competent DB3.1™ E. coli (Thermo Fisher 
Scientific) and resulting vectors were purified using the QIAprep Spin Miniprep Kit (QIAGEN) and 
sequence verified.  
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4.2.3 Cell culture  
On day 1, HUVEC cells (40,000 per well) were plated into 24-well tissue culture plates. On day 2, 
250 ng of luciferase vector and 27.8 ng of renilla vector per well were co-transfected into HUVEC. 
Luciferase and renilla vectors were added to 250 μl of Opti-MEM® Reduced Serum Medium (Life 
Technologies), and 0.5 μl of TransIT®-2020 transfection reagent (Mirus Bio) per well was added to the 
vectors and Opti-MEM. The transfection mixture was incubated for 30 minutes at room temperature and 
then transfected into HUVEC, and cells were incubated for 2 days at 37°C and 5% CO2. Luciferase 
assays were then performed using a GloMax® luminometer (Promega) after 48 hours. 
 
4.2.4 Cloning of PLXND1 candidate cis-regulatory elements into EGFP expression vector 
CRE elements that were cloned into a Gateway pDONR™221 entry clone (Thermo Fisher 
Scientific) as described for the luciferase vectors above were recombined into a pGW_cfosEGFP 
expression vector[188] containing Tol2 sites necessary for transposition into the zebrafish genome. CRE 
elements were recombined by LR recombination using LR Clonase™ according to manufacturer’s 
instructions (Thermo Fisher Scientific) and incubated overnight. The recombination reactions were then 
transformed into Library Efficiency® DH5α™ Chemically Competent E. coli strains, purified using 
PureLink® HiPure Plasmid Miniprep Kit (Thermo Fisher Scientific) and vectors were verified by 
sequencing. 
 
4.2.5 Injection and imaging of human PLXND1 CREs in zebrafish 
 Zebrafish experiments were approved by The University of North Carolina at Chapel Hill and 
Duke University Institutional Animal Care and Use Committees. All injections were performed in 
Tg(kdrl:mCherry)
is5Tg
 zebrafish embryos (hereafter referred to as kdrl:mCherry)[189, 190]. On the day of 
injection, a mix was prepared containing 1 μl pTol2DEST:PLXND1-CRE (125 ng/μl), 1 μl Tol2 
transposase mRNA (175 ng/μl), 0.5 μl Phenol Red (2% in H2O) and 2.5 μl RNase-free water. This mix 
was kept on ice until injection. A 4 nl volume of mix was injected into the cell of 1-cell stage embryos 
using a Picospritzer III Microinjection system (Parker Hannifin Corporation). Injected embryos were kept 
in Embryo Medium in petri dishes at 28.5°C. Embryo Medium consisted of 400 ml of 20X salt (17.5 g 
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NaCl, 0.75 g KCl, 2.9 g CaCl2, 2.39 g MgSO4, 0.41g KH2PO4, 0.13 g Na2HPO4), 16 ml of bicarbonate 
stock (1.5 g NaHCO3 in 50 ml of dH2O) and dH2O. After 8 hours post fertilization (hpf), embryo medium 
was changed and dead embryos were removed. At 24 hpf, embryos were screened for eGFP 
fluorescence on a Leica M205 FA fluorescence stereomicroscope (Leica Microsystems). Embryos that 
exhibited expression of eGFP were then raised to adulthood. These adults were then crossed to 
kdrl:mCherry fish  and their offspring were screened for eGFP fluorescence. Three independent 
transgenic founders were identified with germline transmission of Tg(HSa.CRE17.PLXND1-
Mmu.FOS:GFP) with the following allele designation of rdu1, rdu2 and rdu3. The resulting F1 offspring 
were raised to establish stable transgenic lines. The expression dynamics of eGFP was similar between 
all alleles. F1 Tg(HSa.CRE17.PLXND1-Mmu.FOS:GFP)
rdu3 
adults were again outcrossed to kdrl:mCherry 
fish and the F2 offspring were analyzed by fluorescence stereomicroscopy (as above) at 22hpf and 
120hpf.  
 
4.2.6 Electrophoretic mobility shift assays  
Complementary DNA oligonucleotides (19-bp) centered on variant alleles for rs4488824 were 
synthesized by Integrated DNA Technologies and sequences are noted in Table 4.2. Labeled 
oligonucleotides included biotin on the 5’ end. We performed assays as previously described[83, 85] by 
using 4 µg of HUVEC nuclear lysate and 50-fold excess unlabeled probe. Reactions were loaded into a 
6% DNA retardation gel (Thermo Fisher Scientific), subjected to electrophoresis, transferred to Biodyne B 
nylon membranes (Thermo Fisher Scientific), and UV crosslinked. Wash and detection steps were 
performed according to instructions in the Chemiluminescent Nucleic Acid Detection Module (Thermo 
Fisher Scientific). EMSAs were repeated on a separate day with consistent results. TRANSFAC and 
JASPAR[111] databases were used to search for transcription factor position weight matrices that were 
similar to the human genome sequence containing rs4488824. For supershift assays, 6 µg of MAFB (sc-
22830X) or 6 µg MYOG (Myogenin, sc-31943X) (both from Santa Cruz Biotechnology, Inc.) antibodies 
were incubated with HUVEC nuclear lysate, binding buffer, and poly(dI·dC) for 20 minutes before addition 
of labeled DNA probes. 
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4.3 Results  
4.3.1 Four candidate CREs show enhancer activity in HUVEC 
Considering the relatively wide 31-kb WHR association signal (defined by all variants r
2 
> 0.8 with 
the GWAS associated variant rs10804591) and our observation that all of the WHR-associated variants at 
PLXND1 overlap open chromatin DNase and FAIRE peaks and/or histone modification H3K4me1, 
H3K4me2, H3K9ac, and H3K27ac ChIP-seq peaks in HUVEC (Table 4.1, Figure 4.1), we aimed to 
identify regulatory enhancer elements that influence gene expression. We designed candidate cis-
regulatory elements (CREs) to test in complementary luciferase reporter assays in HUVEC and 
transgenesis reporter assays in zebrafish. Fifteen candidate CREs were originally designed to span 
DNase, FAIRE, H3K4me1, H3K4me2, H3K9ac, and H3K27ac peaks in HUVEC from ENCODE data[72] 
and variants in strong LD (r
2 
> 0.8, 1000 Genomes phase 1 EUR[144]) with the WHR-associated GWAS 
lead variant rs10804591. We were not successful in amplifying 5 CREs that were larger than 3 kb, 
therefore, we revised the candidate CRE list and designed smaller candidate CREs. A total of 10 
candidate CREs span 20 candidate variants (Table 4.1). We successfully PCR-amplified and cloned 7 
candidate CREs to date (CRE 2, 6, 8, 9, 13, 14, 17). Of these, 4 CREs (CRE 8, 9, 13, 17) exhibited 
evidence of transcriptional enhancer activity (1.4-fold to 3.4-fold compared to empty vector control, Figure 
4.2) for the one allele or haplotype that was cloned. Of these, CRE 13 exhibited the strongest enhancer 
activity, suggesting that it could be the strongest enhancer among elements tested. 
 
4.3.2  The alleles of rs11718169 in CRE 17 show similar enhancer activities in HUVEC 
We next investigated whether there were haplotype or allelic differences for candidate CREs that 
demonstrated transcriptional enhancer activity in HUVEC. Specifically, we performed preliminary 
experiments for two of the 4 CREs that contain only a single variant in strong LD (r
2 
> 0.8, 1000 Genomes 
phase 1 EUR[144]) with the lead GWAS WHR-associated variant rs10804591 (CRE 13 and 17). CRE 13 
contains rs4488824 (r
2 
= 0.99 with rs10804591) and CRE 17 contains rs11718169 (r
2 
= 0.91 with 
rs10804591), therefore, it was relatively straightforward to change the alleles of these variants using site-
directed mutagenesis and test for allelic differences in transcriptional enhancer activity. In preliminary 
experiments, the alleles of rs11718169 in CRE 17 showed 7.6- to 10.3-fold enhancer activity compared to 
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empty vector control, however, there were no significant differences observed between the alleles (Figure 
4.3). Plasmids containing both alleles of rs4488824 in CRE 13 have been generated and verified by 
sequencing, however, luciferase reporter assays in HUVEC still need to be performed.  
 
4.3.3 CRE 17 shows enhancer activity in endothelial cells in zebrafish 
To determine whether the CREs could drive tissue-specific expression, we tested whether 
candidate CRE 17 (the CRE tested for allelic differences in transcriptional enhancer activity in HUVEC) 
could drive expression of the reporter gene GFP in zebrafish. We cloned the human CRE 17 element into 
the pGW_cfosEGFP expression vector[188] and injected the CRE 17-containing vector into 1-cell stage 
zebrafish embryos. At 22 hpf, the CRE 17 element (hsPLXND1-CRE17:eGFP) drove GFP expression 
throughout the zebrafish embryo specifically in endothelial cells. GFP expression was observed in the 
cranial vasculature (lateral dorsal aorta), endothelial cells migrating over the yolk (common cardinal vein) 
and truncal vasculature (segmental vessels, dorsal aorta and posterior cardinal vein). These results are 
shown in Figure 4.4 (left panels). To better compare the expression pattern to sites of endothelial cells, 
we crossed hsPLXND1-CRE17:eGFP to an established endothelial cell-specific transgenic line, 
kdrl:mCherry[189, 190]. At 120 hpf, the progeny showed GFP expression co-localized with mCherry 
expression in endothelial cells in the dorsal aorta and posterior cardinal vein (Figure 4.4, right panels). 
The green autofluorescence in pigment cells and intestine (Figure 4.4, lower right panel) does not 
represent specific CRE 17 enhancer activity. The transgenesis assays in zebrafish suggest that CRE 17 
is an endothelial cell-specific regulatory enhancer element in zebrafish. 
 
4.3.4  rs4488824 in CRE 13 exhibits differential protein binding 
Based on CRE 13’s strong enhancer activity in HUVEC transcriptional reporter assays, we 
evaluated whether the WHR-associated variant in CRE 13, rs4488824, exhibits differential protein binding 
of nuclear proteins such as transcription factors. In EMSAs, rs4488824 exhibited a reproducible band for 
the rs4488824-A allele that was not observed for the rs4488824-T allele. This band likely represents 
better binding of a transcription factor to the A allele (Figure 4.5, lane 2 vs. lane 6). The differential band 
was confirmed to be specific through better competition by excess unlabeled DNA containing the 
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rs4488824-A allele than the rs4488824-T allele. The rs4488824 variant is located within predicted MYOG 
and MAFB protein sites. We tested whether antibodies against these proteins could demonstrate specific 
recognition of the bound protein in an EMSA, however, we did not observe evidence of a supershift or 
disruption of the A allele-specific band. Taken together, our EMSA data suggest that rs4488824 within 
CRE 13 binds an unknown transcriptional regulatory protein. 
 
4.4 Discussion 
We identified four candidate cis-regulatory elements that affect regulatory activity at the PLXND1 
locus. Candidate CREs 8, 9, 13 and 17 showed enhancer activity in HUVEC, and the human PLXND1 
CRE 17 element was expressed in endothelial cells in stable transgenic kdrl:mCherry zebrafish lines. 
Together, these data suggest that the transcriptional regulation of CRE17 is conserved between zebrafish 
and humans and may be a functional regulatory element that affects enhancer activity in an endothelial 
cell-specific manner. CRE 13 showed the strongest enhancer activity of the 7 candidate CREs tested in 
HUVEC transcriptional reporter assays, and contains a variant, rs4488824, which showed allelic 
differences in binding of a nuclear protein. These data suggest that rs4488824 may be a functional 
regulatory variant located within an enhancer element in human endothelial cells. While neither the full set 
of candidate WHR variants nor all CREs have been examined, these data support the previous findings 
that plxnd1’s effect on fat deposition and VAT morphology was observed in vascular endothelial cells[187].  
This study highlights the value of using complementary human cell-based and zebrafish 
transgenesis assays to identify regulatory elements. Reporter assays in zebrafish and the generation of 
stable zebrafish lines can provide evidence that a regulatory element acts during a specific 
developmental time point or in a specific cell or tissue. Luciferase reporter assays have been useful in 
identifying regulatory elements[82-85, 191, 192], however, the identification of these elements may be 
hindered by the lack of prior knowledge of the correct cell type in which to conduct the assays. There are 
also limitations to using animal models, as absence of regulatory activity of human candidate CREs could 
be attributed to lack of conservation between humans and zebrafish.  
The EMSA data for rs4488824 in CRE 13 suggest that rs4488824 could be a functional 
regulatory variant responsible for the WHR association that is located within a regulatory enhancer 
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element at the PLXND1 locus. Additional experiments will be necessary to determine the identity and 
validate the protein bound differentially to rs4488824. Additional experiments are also needed to 
determine whether rs4488824 within CRE 13 shows allelic differences in transcriptional regulatory activity, 
as the CRE 13 element containing the rs4488824-T allele was tested in the HUVEC transcriptional 
reporter assays, but not the CRE 13 element containing the rs4488824-A allele. Furthermore, it will also 
be necessary to test CRE 13 in zebrafish transgenesis assays to investigate whether this CRE drives 
temporal or tissue-specific GFP expression. 
CRE 17 showed enhancer activity in HUVEC as well as in endothelial cells in zebrafish. 
Preliminary transcriptional reporter assay experiments in HUVEC did not show allelic differences in 
enhancer activity for rs11718169 (the WHR-associated variant located within CRE 17). These results are 
not unexpected, considering that we observed no noticeable differences in GFP expression between the 
two alleles in the stable transgenic zebrafish lines containing human CRE 17. These data suggest that 
rs11718169 may not drive allelic differences in enhancer activity or be a functional regulatory variant 
responsible for the WHR association. Additional experiments, such as EMSAs, could be performed to test 
whether there is evidence of differential nuclear protein binding at rs11718169. 
More work is necessary to identify all the potential regulatory elements in this region, including 
testing the remaining 3 candidate CREs in both transcriptional reporter assays in HUVEC and 
transgenesis assays in zebrafish. The transcriptional reporter assays in HUVEC took months of 
optimizing due to low transfection efficiency and the fact that HUVEC are sensitive to endotoxins, 
therefore, it will be important to repeat these assays with the optimized conditions to confirm that the 
transcriptional enhancer activities observed for CREs 8, 9, 13 and 17 are reproducible. Low transfection 
efficiency, toxicity and cell death were observed when transfecting greater than 250 ng of plasmids into 
HUVEC; these reasons are likely attributed to the fact we only observed 1.4-fold enhancer activity for 
CRE 17 in our preliminary experiments (Figure 4.2) but 7.6- to 10-fold enhancer activity for CRE 17 in an 
independent experiment after the conditions were optimized (Figure 4.3). It will also be important to test 
both alleles/haplotypes of the WHR-associated variants contained within the candidate CREs to identify 
the potential functional regulatory variants and gain a greater understanding of the direction of effect on 
WHR in humans.   
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Functional investigation of GWAS signals can be challenging, especially if the association signal 
is wide (i.e. there are many candidate variants in strong LD with the GWAS lead variant). Therefore, it can 
be beneficial to identify larger regulatory elements to determine the functional regulatory variant(s) at a 
GWAS locus. Open chromatin and histone modification ChIP-seq peaks have been useful for identifying 
regulatory variants that are responsible for the association signal[85]; however, if all of the variants 
overlap regulatory marks, these marks may not be useful for distinguishing regulatory variants. This study 
shows the benefits of using regulatory datasets combined with experiments in human cell-based assays 
and animal models to identify the functional regulatory elements and variants, as well as the cell types in 
which they act. Another challenge to functional follow-up studies of GWAS loci is determining the target 
gene(s). PLXND1 is a likely target gene influencing WHR, considering plxnd1’s role in adipose 
morphology and lipid storage and the observation that PLXND1 mRNA levels were associated with a 
hypertrophic VAT morphology in humans[187]. However, we cannot rule out the possibility of other target 
genes, considering the published eQTL highlighting an association between the WHR-associated variant 
rs10804591 and TMCC1 expression in 5,311 peripheral blood samples (p= 3.5 x 10
-27
)[164]. The TMCC1 
gene is located 41 kb from PLXND1 and encodes transmembrane and coiled-coil domain family 1 protein, 
which has a suggested role in endoplasmic reticulum organization[193]. Overall, the human GWAS study 
that identified a WHR association signal at the PLXND1 locus[65] and studies on the biological role of 
plxnd1 in adipose morphology and fat storage in zebrafish[187] were undoubtedly valuable for gaining 
greater understanding of PLXND1’s potential role in WHR and body fat distribution.  
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Figure 4.1 Open chromatin and histone modifications marking potential regulatory regions at the 
PLXND1 WHR-associated locus 
A 31-kb region includes all 35 variants in strong linkage disequilibrium (r
2 
> 0.8, 1000 Genomes phase 1 
EUR) with the WHR-associated lead GWAS SNP rs10804591 (36 total candidate variants). Selected 
Roadmap Epigenomics Human Epigenome Atlas histone modification ChIP-seq and ENCODE open 
chromatin, and histone modification ChIP-seq signal and peak tracks are shown for adipose nuclei 
(green) and human umbilical vein endothelial cells (HUVEC, designated by orange). ENCODE histone 
modification ChIP-seq peaks in HUVEC show broad patterns of H3K4me1-, H3K4me2-, H3K4me3-, 
H3K9ac- and H3K27ac-enriched domains[118]. Darker-shaded enrichment domains for these histone 
marks (indicated by the gray and black-shaded rectangles over the histone modification signals) signify 
higher browser extensible data (BED) score values. The black vertical lines above the PLXND1 gene 
represent all 36 total candidate variants (labeled as WHR variants).  
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Figure 4.2 Four PLXND1 candidate cis-regulatory elements show enhancer activity in HUVEC 
transcriptional reporter assays 
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Figure 4.2 Four PLXND1 candidate cis-regulatory elements show enhancer activity in HUVEC 
transcriptional reporter assays 
The rectangles designated by “CRE” indicate candidate cis-regulatory elements that overlap with open 
chromatin or histone modification ChIP-seq marks and WHR-associated variants in PLXND1 intron 1 or 
upstream of the PLXND1 promoter. The blue rectangles indicate CRE elements that have been cloned 
into gateway compatible luciferase plasmids and tested in luciferase assays in HUVEC, and black 
rectangles indicate CREs that have been designed but not cloned. The bottom of the figure indicates the 
relative luciferase expression of the candidate CREs tested (one haplotype for each CRE was tested). 
WHR variants indicate variants in strong LD (r
2 
> 0.8, 1000 Genomes phase 1 EUR) with the GWAS-
associated lead variant rs10804591 (36 total candidate variants). CRE, cis-regulatory element. 
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Figure 4.3 Both alleles of rs11708067 in CRE 17 exhibit enhancer activity in HUVEC transcriptional 
reporter assays 
888-bp segments containing each allele of rs11708067 were cloned into a gateway-compatible pGL4.23 
luciferase reporter vector upstream of the minimal promoter. The vectors were transfected into HUVEC 
cells, and luciferase expression normalized to that of an empty vector control is shown. Error bars 
represent the pairwise standard deviation of four independent clones per allele. 
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Figure 4.4 CRE 17 shows enhancer activity in endothelial cells in zebrafish 120 hours post-
fertilization  
1-cell stage zebrafish embryos were injected with 125 ng of plasmid containing hsPLXND1-CRE17:eGFP 
with transposase mRNA. Embryos that exhibited eGFP expression were raised to adulthood and crossed 
to kdrl:mCherry zebrafish. F1 offspring were raised to establish stable transgenic lines and F1 
hsPLXND1-CRE17:eGFP adults were outcrossed to kdrl:mCherry zebrafish. F2 offspring were analyzed 
by fluorescence stereomicroscopy at 22 hpf (left panels) and 120 hpf (right panels).  
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Figure 4.5 rs4488824 (in CRE 13) shows allelic differences in protein binding 
EMSAs with biotin-labeled probes containing either the A or T allele of rs4488824 and incubated with 4 
μg HUVEC nuclear lysate. The arrow indicates specific protein binding to the A allele (lane 2 versus 6). 
For competition reactions, 50-fold excess unlabeled probe containing either allele were added. 
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Candidate CRE Location with 
respect to 
PLXND1 
Size of element in 
bp 
Overlapping WHR-
associated variants 
Regulatory marks 
in HUVEC 
1 3 kb upstream 
PLXND1 
1479 rs9840468, 
rs11929498, 
rs9845755, 
rs9808900 
DNase, FAIRE, 
H3K4me1, 2, 3; 
H3K9ac, 
H3K27ac 
2 PLXND1 intron 1 2262 rs1872113 DNase, FAIRE, 
H3K4me1, 2, 3; 
H3K9ac, 
H3K27ac 
3 PLXND1 exon 1, 
5’UTR, TSS and 3 
kb upstream 
4180, contains 
PLXND1 TSS 
- DNase, FAIRE, 
H3K4me1, 2, 3; 
H3K9ac, 
H3K27ac 
6 PLXND1 intron 1 1072 rs1872113 DNase, 
H3K4me1, 2, 3; 
H3K9ac, 
H3K27ac 
7 PLXND1 intron 1 3472 rs281448, 
rs57098603, 
rs11711654, 
rs9837325, 
rs4579013 
DNase, FAIRE, 
H3K4me1, 2, 3; 
H3K9ac, 
H3K27ac 
8 PLXND1 intron 1 2614 rs6792344 
rs9682596 
DNase, FAIRE, 
H3K4me1, 2, 3; 
H3K9ac, 
H3K27ac 
9 PLXND1 intron 1 1878 rs6786987, 
rs6774878, 
rs2811450 
DNase, FAIRE, 
H3K4me1, 2, 3; 
H3K9ac, 
H3K27ac 
13 5 kb upstream of 
PLXND1 
1589 rs4488824 DNase, FAIRE, 
H3K4me1, 2; 
H3K9ac, 
H3K27ac 
14 11 kb upstream of 
PLXND1 
2506 rs6778532, 
rs4688808, 
rs2811437 
DNase, FAIRE, 
H3K4me1, 2, 3; 
H3K9ac, 
H3K27ac 
17  26 kb upstream of 
PLXND1 
888 rs11718169 DNase, FAIRE, 
H3K4me1, 2; 
H3K9ac, 
H3K27ac 
Table 4.1 Summary of candidate cis-regulatory elements designed to test in luciferase reporter 
assays and zebrafish transgenesis assays 
CRE, cis-regulatory element; TSS, transcriptional start site; 5’ UTR, 5’ untranslated region; HUVEC, 
human umbilical vein endothelial cells. Regulatory marks in HUVEC indicate that the CRE overlaps at 
least 200 base pairs of an ENCODE-defined regulatory peak (DNase, FAIRE, H3K4me1, H3K4me2, 
H3K4me3, H3K9ac or H3K27ac peaks). 
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Primer sequences for amplifying PLXND1 CREs  
CRE1_Forward 
CRE1_Reverse 
 
ACACCTTCCCTGGCCTTACT 
GTGTCCCCATCTGCAAAAGT  
CRE2_Forward 
CRE2_Reverse 
 
CTCCAGGACCAAGCAGAGAC 
CATGCCTGACCAAAGTTGTG 
CRE3_Forward 
CRE3_Reverse 
 
CGTGCATACCTGGGCTTTAT 
GAGCCTTGTTGTGCTTGACA 
CRE6_Forward 
CRE6_Reverse 
 
CTGCATTTTGCTGATGGAGA 
GTTACCATTGCACGTTGGTG 
CRE7_Forward 
CRE7_Reverse 
 
 
CCTGGAAAAGAAAGCAGACG 
CCTGCAGGCTAAAGACTTGG 
CRE8_Forward 
CRE8_Reverse 
 
ACCTCCTCCCTCACCATTCT 
TCAGTGCAGCATTTTCAAGG 
CRE9_Forward 
CRE9_Reverse 
CTCCCACCAAGGGAACATAA 
CAGCTCTGTGGCAAATTTCA 
CRE13_Forward 
CRE13_Reverse 
 
TTGACCGTGTTTCCAGACAG 
GGCCTGTGTGCATCTGATAA 
CRE14_Forward 
CRE14_Reverse 
 
CCAGAAGGATCTGGGTTCAA 
CTCCTGTGGGTCTGTCCTGT 
CRE17_Forward 
CRE17_Reverse 
 
 
GGGGACTGTGAAGACAGGAG 
CCTGGCCCTAATCTCCTCAT 
Probe sequences for EMSAs  
rs4488824_A_Forward (with respect to the 
genome) 
rs4488824_T_Reverse 
CAGCTGTGCAGCTGACCCC 
 
GGGGTCAGCTGCACAGCTG 
rs4488824_T_Forward (with respect to the 
genome) 
rs4488824_A_Reverse 
CAGCTGTGCTGCTGACCCC 
 
GGGGTCAGCAGCACAGCTG 
 
Table 4.2 Primer sequences for functional assays 
All sequences are shown 5’-3’ with respect to the genome. 
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CHAPTER 5: CONCLUSIONS 
GWAS have identified thousands of variants associated with complex traits and diseases[194, 
195]. However, many of the molecular and biological mechanisms responsible for these associations are 
complex and identifying the causal variants and genes can be challenging. Contributing to this complexity 
is the fact that many of the variants discovered through GWAS are located within noncoding or intergenic 
regions[68, 95] which can make it difficult to identify the target genes, especially if the variant is located 
within a gene-dense region of the genome. The noncoding variants also make it challenging to determine 
the molecular mechanism(s) responsible for the association, because the variants often act to regulate 
expression of a gene, in contrast to altering the structure or function of a protein. Variants can also act to 
regulate genes across long distances[196, 197], which can make the identification of target genes 
challenging. Identifying the functional causal variant(s) at a locus and the gene(s) they may regulate is a 
crucial step in understanding the molecular mechanism(s) and biology underlying an association. This 
can ultimately provide insight into the direction of effect in humans and lead to a greater understanding of 
how genetic variation can contribute to complex metabolic traits, such as lipid and cholesterol levels, type 
2 diabetes and WHR.  
In the previous chapters, I described the functional follow-up of three GWAS loci associated with 
metabolic traits and disease. I identified multiple regulatory variants at the GALNT2 HDL-C-associated 
locus[85]; at least two of these variants, rs4846913 and rs2281721, exhibited strong haplotype and allelic 
differences in transcriptional enhancer activity and differential protein binding in EMSAs (described in 
Chapter 2). The alleles associated with increased HDL-C also showed an association with increased 
GALNT2 expression in primary human hepatocyte samples and subcutaneous adipose tissue samples, 
providing new clues into the direction of effect in humans that contrasts with previous findings based on 
GALNT2 and HDL studies in mice[87]. At the ADCY5 locus associated with T2D and glucose-related 
traits, I identified a functional regulatory variant, rs11708067, which is located within enhancer elements 
in human pancreatic islets (described in Chapter 3). Histone modification H3K27ac ChIP-seq reads,
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which often mark transcriptional enhancer regions, showed significant allelic imbalance spanning 
rs11708067 in human pancreatic islets, and this variant also exhibited allelic differences in enhancer 
activity and differential protein binding. The T2D-risk allele of rs11708067 also showed an association 
with decreased ADCY5 expression in human pancreatic islets. Finally, at the PLXND1 locus associated 
with human WHR, I identified four regulatory elements that demonstrated enhancer activity in human 
umbilical vein endothelial cells, one of which also exhibited enhancer activity in endothelial cells in 
zebrafish (described in Chapter 4). These studies highlight the often complex molecular and biological 
mechanisms that are responsible for genome-wide associations, and underscore the value of using 
functional follow-up studies to further understand the genetic contribution of complex traits.  
Many functional studies have reported single regulatory variants that likely drive the association 
signal[69, 81-84]. At other GWAS loci, multiple variants may influence the association signal. Functional 
studies on the GALNT2 GWAS HDL-C locus showed that multiple noncoding variants in strong (or even 
moderate) linkage disequilibrium likely contribute to gene regulatory function and bind various 
transcription factors in a complex in an allele-specific manner. At least 2 regulatory variants, rs4846913 
and rs2281721, showed strong allelic differences in transcriptional enhancer activity and differential 
protein binding in EMSAs. rs2144300 also showed evidence of allelic effects on enhancer activity when 
tested together with rs4846913 in a 780-bp element, and showed suggestive differences in transcription 
factor binding in EMSAs. Finally, variants rs1555290 and rs6143660 also exhibited differential protein 
binding in EMSAs. The observation that at least 4 GALNT2 variants showed allelic differences in protein 
binding is not unexpected; a previous study showed that the majority of candidate regulatory variants at 
platelet quantitative trait loci overlapped transcription factor binding sites and affected binding[198]. 
Considering the numerous transcription factor ChIP-seq peaks from ENCODE data[72] that overlap 
GALNT2 variants rs4846913, rs2144300, rs1555290 and rs6143660, it is possible that additional factors 
beyond those we identified bind to one or more of these variant(s) and may regulate expression of 
GALNT2 or some other gene. More experiments are necessary to determine the identities of these 
proteins and to further investigate whether these factors contribute to allelic differences in regulatory 
activity. At the ADCY5 locus, I identified a single variant, rs11708067, which influences regulatory activity 
and is associated with ADCY5 expression. However, it is important to note that additional experiments will 
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be necessary to determine whether other variants also show evidence of allelic differences in regulatory 
activity or protein binding. The two additional variants in strong LD with rs11708067 are also located 
within predicted pancreatic islet enhancer regions, supporting their possible role in ADCY5 regulation. At 
the PLXND1 locus, we have identified multiple regulatory elements, which overlap numerous variants in 
strong linkage disequilibrium (r
2 
> 0.8) with the WHR-associated lead GWAS variant. At least one of these 
variants affects transcription factor binding. Identification of multiple regulatory elements at the PLXND1 
locus suggests that there are also multiple functional regulatory variants, however, more experiments will 
be necessary to determine the full set of variants that exhibit regulatory activity. 
 Open chromatin, chromatin state, histone modification ChIP-seq and transcription factor ChIP-
seq data have been successful at guiding the identification of regulatory variants at GWAS loci[79-84]. At 
the ADCY5 locus, rs11708067 was a plausible candidate regulatory variant based on its location within a 
strong enhancer chromatin region and overlap with DNase and FAIRE peaks in human pancreatic islets. 
As predicted, it showed allelic differences in transcriptional enhancer activity and differential transcription 
factor binding. However, at other loci, regulatory data may not be informative in pinpointing functional 
variants, as is the case with the PLXND1 WHR-associated locus. Of 35 variants in strong linkage 
disequilibrium (r
2 
> 0.8, 1000 Genomes phase 1 EUR) with the lead GWAS variant, all of the variants 
overlap at least one mark of open chromatin and/or histone modifications marking active regulatory 
regions. Therefore, a more comprehensive approach (i.e. testing all candidate variants in strong linkage 
disequilibrium or testing larger regions that encompass many variants) are necessary to identify the 
causal variants. At the GALNT2 HDL-C-associated locus, regulatory datasets were useful in predicting 
rs4846913, rs2144300, rs1555290 and rs6143660 as likely functional regulatory variants, as these 
variants overlapped the most regulatory marks of all candidate variants. However, testing all candidate 
variants in strong linkage disequilibrium (r
2 
> 0.7, 1000 Genomes phase 1 EUR) with the lead GWAS 
variant enabled us to identify rs2281721 as an additional regulatory variant that showed the strongest 
evidence of enhancer activity in reporter assays at the GALNT2 locus. Overall, regulatory datasets such 
as those generated by the ENCODE project[72] and Roadmap Epigenomics Consortium[73] can be used 
as a guide for identification of functional regulatory variants, but solely using these datasets to prioritize 
variants for functional follow-up studies may result in overlooking others that exhibit regulatory function.  
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My studies on the GALNT2 locus have highlighted some of the limitations to using in vitro assays, 
such as luciferase reporter assays and EMSAs, for functional follow-up of GWAS loci. One of these 
limitations is the luciferase reporter assay relies on a segment of DNA cloned into a reporter vector, which 
does not reflect the actual chromatin conformation of the element in the genomic context of cells. While 
we were able to identify multiple regulatory variants at the GALNT2 locus through luciferase assays, it is 
possible that additional variants also exhibit regulatory function, but were not detected because the DNA 
element was not in its natural chromatin conformation in the cell. Another important issue to consider 
when deciding which elements to test in these assays is the size of the element cloned within the vector. 
rs4846913 only showed strong allelic differences in enhancer activity within a larger 780-bp segment with 
additional variants rs2144300, rs1555290, and rs6143660; it did not show allelic effects on enhancer 
activity when tested individually in a 120-bp segment. This suggests that some variants at GWAS signals 
may show regulatory activity that is genomic context-specific; that is, larger segments of DNA that 
encompass regulatory marks such as open chromatin, histone modifications or transcription factor 
binding sites may be necessary to exhibit allelic effects on transcription. Another study[199] has 
confirmed that the context of a larger 489-bp segment encompassing rs4846913, as well as a 608-bp 
segment containing both rs4846913 and rs2144300 are necessary to observe allelic differences in 
transcriptional enhancer activity (Figure 5.1) which supports the conclusion that for some variants, it is 
necessary to test larger segment sizes in order to incorporate the whole regulatory element.  
There are also limitations to in vitro EMSAs, which examine protein binding by taking the DNA out 
of the chromatin context in a cell. rs2281721 showed C-allele specific binding of USF-1 in EMSAs, 
however, I did not observe statistically significant allelic differences in USF-1 binding in two independent 
ChIP experiments (a more in vivo context) in HepG2 and Huh-7 cells. These inconsistent results could be 
the result of sub-optimal conditions for protein binding in the in vitro context of an EMSA. The strong 
allelic differences in transcriptional enhancer activity and USF-1 ChIP results for the rs2281721 region 
suggest that another transcription factor besides USF-1 may also bind to rs2281721 and cause the allelic 
differences in enhancer activity. USF-1 has been shown to bind with other transcription factors[200-202], 
therefore, other transcription factors bound to USF-1 may be necessary to affect allele-specific regulatory 
activity. Experiments to alter USF-1 expression (via overexpression or knockdown methods) will be 
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necessary to fully interrogate whether USF-1 influences expression of GALNT2, although the effects on 
expression may be modest and similar to what we observed with siRNA-mediated knockdown of CEBPB. 
As we progress through the GWAS era into follow-up studies, fine-mapping analyses, as well as 
functional studies, are useful tools to refine GWAS signals and determine the functional candidate 
variants responsible for these signals. Fine-mapping and imputation strategies involve using linkage 
disequilibrium patterns to infer haplotypes in many individuals; therefore, these methods take into 
consideration numerous additional variants besides those that were directly genotyped[203-205]. Fine-
mapping and conditional analyses indicate whether an association is a single signal consisting of 
common variants, or if there are underlying secondary (or additional) signals that are the result of other 
functional variants in moderate to weak LD with the lead GWAS variant[206, 207]. These fine-mapping 
and conditional analyses were very valuable for the further characterization of the HDL-C association 
signal at GALNT2 and helped to distinguish that the HDL-C association consists of a single signal of the 
common GWAS-identified variants in strong linkage disequilibrium in intron 1. Fine-mapping has also 
aided in the characterization of association signals for fasting proinsulin and/or T2D[83, 172]. Additionally, 
trans-ancestry fine-mapping approaches can also be useful for refining association signals for complex 
traits because they take into consideration the differing LD patterns between populations. Trans-ancestry 
fine-mapping has helped to refine association signals, including associations for T2D[67, 208] and 
lipids[207]. These approaches also refined the LDL-C association signal at the SORT1 locus and guided 
the identification of a functional regulatory variant[69]. Incorporating fine-mapping and/or trans-ancestry 
fine-mapping methods in future studies on the T2D and WHR association signals at the ADCY5 and 
PLXND1 loci, respectively, may be useful for further characterization of these association signals and for 
identification of the likely functional variants. 
Functional studies in model organisms are also useful tools to understanding the underlying 
biology of GWAS loci. Using zebrafish transgenesis assays and creating stable lines were valuable in 
confirming that a regulatory element showing enhancer activity in HUVEC was conserved and also 
showed enhancer activity in endothelial cells in zebrafish. Using zebrafish transgenesis assays to identify 
cis-regulatory elements at the PLXND1 locus were beneficial because they provided information about 
the spatial and temporal regulation by the enhancer element, CRE 17, which is not possible with 
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luciferase assays in cell lines. Using model systems such as zebrafish and mice may also provide a 
greater understanding of the relationship between GWAS target genes and metabolic traits and the 
direction of effect in humans. At the GALNT2 HDL-C-associated locus, we observed a consistent 
direction of effect with the human GWAS variants and recent studies showing that total loss of function of 
GALNT2 in human, mouse, rat and cynomolgus monkey all resulted in lower HDL-C (Khetarpal et al. 
2013 abstract for The American Society of Human Genetics annual meeting). However, previously 
published Galnt2 overexpression and knockdown studies in mice using adeno-associated viral vectors 
showed the opposite direction of effect[87]. These observations may be attributed to differences between 
partial loss of function knockdown and total knockout studies, or due to the fact that adenoviral vectors 
can have toxic effects[209], which may be confounding the effects on HDL-C. It is important to note that in 
some cases, using model organisms to study the molecular mechanisms that are responsible for GWAS 
signals can also be challenging, because of the innate species differences (i.e. lack of conservation of 
gene structure or gene regulatory elements) between animal models and humans. However, utilizing both 
human cell-based and animal models is ideal to gain further understanding of the relationship between 
the GWAS variants and their target genes, as well as how the target genes influence the trait or disease 
of study. 
Additional experiments will be important for fully characterizing the molecular mechanisms 
responsible for the GWAS signals at the GALNT2, ADCY5 and PLXND1 loci. While we observed 
associations between the alleles of GWAS-associated variant rs4846914 and GALNT2 expression in both 
human hepatocyte samples and subcutaneous adipose tissue samples[85] and an association between 
the alleles of rs11708067 and ADCY5 expression in primary human islets, these associations do not 
prove that there is a direct interaction between the GWAS variants and the GALNT2 or ADCY5 gene 
promoters. It would be ideal to perform chromosome conformation capture experiments[210] to 
interrogate the potential gene targets of the identified enhancer elements at the GALNT2, ADCY5 and 
PLXND1 loci and to further characterize the molecular mechanisms for the GALNT2 and ADCY5 
expression quantitative trait loci. Future studies utilizing human induced pluripotent stem cells (iPSCs) 
may also be helpful to gain a better understanding of the molecular and biological mechanisms at the 
GALNT2, ADCY5 and PLXND1 loci. The iPSCs could be differentiated into various cell types of interest 
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(i.e. hepatocytes for GALNT2, pancreatic islets for ADCY5 or adipose endothelial cells for PLXND1) and 
transcriptional reporter assays could be performed to determine in which cell types the regulatory 
enhancers act. Additionally genome editing by CRISPR-Cas9 technology[211-213] could be used to 
generate cells of different genotypes in order to test which variants at the ADCY5 and PLXND1 loci affect 
expression of ADCY5 and PLXND1, respectively, or if the variant affect expression of other nearby genes. 
Additional experiments will be necessary to further characterize the molecular mechanisms at the ADCY5 
and PLXND1 loci. These experiments include testing whether there are additional functional regulatory 
variants at the ADCY5 locus, as there are other likely candidates located within predicted regulatory 
elements, and to identify the protein differentially bound to rs11708067. At the PLXND1 locus, amplifying, 
cloning and testing the remainder of the candidate CREs in HUVEC transcriptional reporter assays and 
zebrafish transgenesis assays will be necessary to determine if there are additional regulatory elements. 
Further investigation of which candidate CREs at the PLXND1 locus contain the functional variants that 
drive the WHR association is also essential to characterizing how these variants act to influence body fat 
distribution. 
My dream experiments for future follow-up studies include using genome editing technologies (i.e. 
CRISPR-Cas9) to alter regulatory enhancer regions and to investigate the effects on expression of 
candidate target genes. I would perform these genome editing experiments in primary human cells and 
tissues. Additionally, I would conduct these experiments using induced pluripotent stem cells before and 
after differentiation into multiple cell types to investigate whether functional regulatory variants or 
enhancer elements function at a specific developmental time point or in a specific cell type. I would also 
perform chromosome conformation capture experiments to validate a direct connection between identified 
regulatory enhancer elements at GWAS loci and target gene promoters. I would use a more high-
throughput approach to investigate the functional regulatory variants and elements at GWAS loci; this 
approach would incorporate high-throughput transcriptional reporter assays and chromosome 
conformation capture experiments to more comprehensively identify regulatory variants and target genes 
and characterize the molecular mechanisms at GWAS loci for metabolic traits. Finally, I would also study 
the biology of novel genes identified through GWAS using model organisms such as mice and zebrafish. 
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Studies such as gene knockout experiments in animal models can ultimately help to characterize the 
biological mechanisms and pathways that influence the metabolic trait or disease of interest. 
Overall, the studies described in Chapters 2, 3 and 4 provide examples of what GWAS functional 
follow-up studies entail and highlight the complexity of determining the underlying molecular and 
biological mechanisms that are responsible for complex metabolic traits. Multiple regulatory variants can 
contribute to association signal(s) and be located within regulatory elements that influence expression of 
target genes. Using regulatory datasets can be useful to pinpoint the most likely candidate regulatory 
elements or variants, but performing functional assays and experiments to determine all of the potential 
regulatory elements and variants are essential. Ultimately, these GWAS follow-up studies can help to 
identify the direction of effect in humans and how the associated variants influence metabolic traits and 
diseases, such as HDL-C, T2D and WHR. 
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Figure 5.1 Allele and haplotype differences in transcriptional enhancer activity are dependent on 
size of segment cloned into the luciferase reporter vector 
Top: Genome browser view of elements tested in luciferase reporter assays (blue, orange and black 
rectangles) and their overlap with HDL-C-associated variants rs4846913, rs2144300, rs6143660 and 
open chromatin and histone modifications. 
Bottom: Relative luciferase activities of a 780-bp segment containing the AT- haplotype or CC+ haplotype 
of rs4846913, rs2144300 and rs6143660; 120-bp segment containing the A or C allele of rs4846913; 608-
bp segment containing the AT haplotype or CC haplotype of rs4846913 and rs2144300 and 489-bp 
segment containing the A or C allele of rs4846913. Relative luciferase activity is shown on the x-axis.
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